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ABSTRACT
Deregulation of the retinoblastoma protein (pRB) pathway is a hallmark of 
cancer, and in the absence of other genetic alterations, results in lack of 
differentiation, hyperproliferation and apoptosis. pRB acts as a transcriptional 
repressor by targeting the E2F transcription factors whose functions are 
required for S phase entry.
Increased E2F activity can induce S phase in quiescent cells and this fact is a 
central element of most models for the development of cancer. I provide 
evidence that E2F1 alone is not sufficient to induce S phase in diploid mouse 
and human fibroblasts. However, increased E2F1 activity can result in S 
phase entry in diploid fibroblasts in which the p53-mediated G l checkpoint is 
suppressed. Furthermore, I show that E2F1 can induce S phase in primary 
mouse fibroblasts lacking pRB. These results demonstrate that in addition to 
working as an E2F-dependent transcriptional repressor, pRB is also required 
for retaining the G l checkpoint in response to unprogrammed proliferative 
signals.
The role of E2F in cell proliferation is not completely understood because it is 
not known if the E2Fs mainly function as transcriptional repressors or
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activators. E2Fs need dimérisation with a DP protein to give rise to functional 
E2F activity and to regulate promoters containing E2F binding sites. I 
inactivated endogenous DP in tissue culture by RNA interference providing 
evidence that loss of DPI abrogates E2F DNA binding activity. DP is required 
for tumour and normal cell growth. In addition, the expression of E2F target 
genes is severely impaired. These results define a crucial role for DPI in cell 
proliferation.
INTRODUCTION
THE E2F FAMILY OF TRANSCRIPTION FACTORS
Eight human genes have been identified as components of the E2F 
transcriptional activity in mammals (Dyson, 1998). On the basis of sequence 
homology and functional properties, these genes have been divided into two 
distinct groups: the E2Fs {E2F1- E2F6) and the DPs {DPI and DP2). Their 
protein products have highly conserved DNA-binding domains and 
dimerization domains. The carboxy-terminal portion of E2F1-5 contains a 
potent transactivation domain but no equivalent activity has been found in 
E2F6 or in DP proteins (Figure A).
E2F and DP proteins heterodimerize to give rise to functional E2F activity and 
to regulate promoters containing E2F binding sites. All possible combinations 
of E2F-DP complexes exist in vivo: Chromatin-Immunoprecipitation (ChIP) 
assays have failed to detect any specificity for the association of individual 
E2F-DP complexes to various known E2F-responsive promoters (Takahashi 
et al., 2000). However, the individual E2F-DP species invoke very different 
transcriptional responses depending on the identity of the E2F moiety and the 
proteins that are associated with the complex.
On the basis of transcriptional properties, the E2F family can be divided into
three distinct subgroups. E2F1, E2F2 and E2F3 are potent transcriptional 
activators. By contrast, E2F4 and E2F5 seem to be primarily involved in the 
active repression of E2F responsive genes by recruiting the pocket proteins 
and their associated histone-modifying enzymes. Finally, E2F6 acts as a 
transcriptional repressor, but in a pocket-protein-independent manner.
Much less is known about the roles of the DPI and DP2 in vivo. DPI is 
ubiquitously expressed at high levels in tissues and in cell lines. DP2 is 68% 
identical to DPI and is expressed at low levels with alternative splicing in a 
restricted set of tissues and cell lines (Wu et al., 1995). When overexpressed 
with various E2F partners and pRB family members, DPI and DP2 function in 
the same way in in vitro assays, such as those for heterodimerization, DNA 
binding and transactivation.
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Figure A - The E2F family o f transcription factors.
The ‘activating^ E2Fs
The founding member of this subclass, E2F1, was cloned by virtue of its 
ability to interact with pRB (Helin et ah, 1992; Kaelin et ah, 1992). E2F1 
binds to DNA in a DP-dependent manner, and the resulting complex is a 
potent transcriptional activator of E2F-responsive promoters (Bandara et ah, 
1993; Helin et ah, 1993b; Krek et ah, 1993). E2F2 and E2F3 are highly 
homologous to E2F1 in the domains that are responsible for DNA binding, DP 
dim erization and pRB binding (Figure A) and they show sim ilar 
transactivation properties. The E2F1, E2F2 and E2F3 expression is regulated 
by cell growth, with maximal accumulation at the G l/S  boundary. They 
associate exclusively with pRB and play a positive role in cell cycle 
progression.
The E2f3 locus expresses two distinct transcripts (Leone et ah, 2000). The 
longer transcript encodes the original E2f3 species, designated E2f3a. The 
second transcript, named E2f3b, is transcribed from a previously unrecognized 
promoter in the first intron of E2f3a, and its protein product is identical to 
E2f3a except that it lacks the amino-terminal domain (Leone et ah, 2000). 
E2F3b is not regulated by cell growth and can be found in both quiescent and 
proliferating cells, but its properties have yet to be described.
E2F1, E2F2 and E2F3 are potent transcriptional activators of E2F responsive 
genes (Helin et ah, 1992; Lees et ah, 1993). Overexpression of any of these
proteins alone or in combination with DPs is sufficient to induce immortalized 
quiescent cells to re-enter the cell cycle (Johnson et ah, 1993; Lukas et ah, 
1996; Qin et ah, 1994). This requires functional DNA-binding and 
transcriptional activity. Some evidences indicate that endogenous E2F1, E2F2 
and E2F3 control cellular proliferation. Microinjection of anti-E2F3 antibodies 
causes decreased S-phase entry in REF52 cells (Leone et ah, 1998). E2f3- 
deficient mouse embryonic fibroblasts (MEFs) are defective in the mitogen- 
induced activation of many E2F-responsive genes and this reduces the rate of 
proliferation of both primary and transformed cells (Humbert et ah, 2000b). 
Finally, the combined inactivation of E 2 fl , E2j2 and E2f3 blocks cellular 
proliferation (Wu et ah, 2001) suggesting that the activating E2Fs could have 
overlapping roles in the induction of cell-cycle entry.
E2F1, E2F2 and E2F3 could also contribute to the repression of E2F- 
responsive genes by recruiting pRB. However, overexpression assays and 
mutant mouse models indicate that the key role of these three E2Fs is the 
activation of genes that are essential for cellular proliferation and the induction 
of apoptosis.
To delineate the functional roles within the E2F family, mice deficient in 
individual £"2/genes have been generated. E2fl-/~ mice are viable and fertile, 
but they have various tissue-specific abnormalities due to defects in apoptosis 
(Field et ah, 1996; Yamasaki et ah, 1998; Yamasaki et ah, 1996): for instance.
they have an excess of T cells and develop testicular atrophy between 9 and 12 
months of age. Most surprisingly, the E 2fl deficient mice are tumour-prone 
and develop a broad spectrum of tumours (lymphoma, lung adenocarcinoma, 
uterine sarcoma) at an age between 8 and 18 months. However, loss of E2fl 
can reduce the pituary and thyroid tumorigenesis in Rb+/~ mice (Yamasaki et 
al., 1998) and can also reduce the nervous system and erythropoietic defects in 
the Rb-/- embryos (Tsai et al., 1998). Inactivation of E 2fl results in viable 
adults that, when crossed to E2fl deficient mice, are highly tumour prone with 
deep effects on hematopoietic cell proliferation and differentiation (Zhu et al., 
2001). By contrast, a significant proportion of the E 2f3-I- mice die in utero, 
and most of the adult survivors die prematurely of congestive heart failure 
without obvious tumour predisposition (Humbert et al., 2000b). Whereas mice 
null for E2fl and E2f2 are viable, mice null for E2fl and E2f3 or E2f2 and 
E2f3 die early during embryonic development pointing at a central role for 
E2f3 in mouse development (Cloud et al., 2002; Wu et al., 2001).
The ‘repressive^ E2Fs
The second subclass of the E2F family includes E2F4 and E2F5. These E2Fs 
were originally identified and cloned by virtue of their association with p i07 
and p i 30 (Hijmans et al., 1995; Vairo et al., 1995). Their sequences diverge 
considerably from those of the activating E2Fs (Figure A). E2F4 and E2F5 
lack most of the sequence that is amino-terminal to the DNA-binding domain 
and are regulated differently from the activating E2Fs in vivo. First, they are
not transcriptionally regulated in cell growth: whereas E2F1, E2F2 and E2F3 
are primarily restricted to actively dividing cells, significant levels of E2F4 
and E2F5 are detected both in quiescent (GO) and proliferating cells (Ikeda et 
ah, 1996; Moberg et al., 1996). Second, the E2F subgroups bind to different 
pocket proteins in vivo. The activating E2Fs are specifically regulated by pRB, 
E2F5 is mainly regulated by p i 30, and E2F4 associates with each of the 
pocket proteins at different points in the cell cycle. As E2F4 is expressed at 
higher levels than the other E2F family members, it accounts for at least half 
of the pRB-, pl07- and pl30-associated E2F activity in vivo. Because of the 
accumulation of E2F4 or E2F5 complexes in quiescent cells, together with the 
fact that many E2F target genes are subject to E2F-dependent repression in 
quiescent cells, these complexes have been suggested to function mainly as 
repressor.
In contrast to the activating E2Fs, E2F4 and E2F5 are poor transcriptional 
activators in overexpression assays, and they cannot drive quiescent cells to 
re-enter the cell cycle (Müller et al., 1997; Verona et al., 1997). The 
differential activity of the two E2F subgroups results from differences in their 
sub-cellular localization: E2F1, E2F2 and E2F3 are constitutively nuclear, 
whereas E2F4 and E2F5 can be found both in the nucleus and in the 
cytoplasm of quiescent cells, but relocate almost entirely to the cytoplasm 
once cells reach S phase. The nuclear localization of the activating E2Fs 
depends on a canonical basic nuclear localization signal (NLS) in their amino-
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terminal domain. On the other hand, some experiments suggest that E2F4 and 
E2F5 localize to the nucleus because of their interaction with pRB or p i 30 
(Verona et al., 1997). E2F4 has two leucine/isoleucine-rich hydrophobic 
nuclear export signals (NES) and its cytoplasmic localization is dependent on 
the nuclear export factor CRMl (Gaubatz et al., 2001).
In GO/Gl cells, E2F4 and E2F5 account for most of the nuclear E2F 
complexes. As these complexes associate with HDACs in vivo (lavarone and 
M assague, 1999), they are thought to be crucial for mediating the 
transcriptional repression of E2F responsive genes. MEFs mutant for E2f4, 
E2f4 and E2f5, or p l0 7  and p i 30 have defects in their ability to exit the cell 
cycle in response to various grow th-arrest signals, including p i 6 
overexpression and contact inhibition (Gaubatz et al., 2000). This correlates 
with the inappropriate expression of a subset of E2F-responsive genes 
(Hurford et al., 1997). However, these mutant cells can all respond 
appropriately to growth-stimulatory signals and there is no detectable change 
in their proliferative capacity.
E2F4 and E2F5 also play a role in the regulation of differentiation. 
Overexpression of E2F4 is sufficient to trigger the differentiation of neuronal 
precursors. Moreover, the developmental defects in the E2f4 and E2f5 mutant 
mouse strains result from lack of differentiation of various cell lineages. Loss 
of E2f4 leads to neonatal death with abnormal hematopoiesis and intestinal 
defects (Humbert et al., 2000a), while the newborn E2f5-I- mice die for
abnormal development and function of choroid plexus, where E2F5 is highly 
expressed (Lindeman et al., 1998). Finally, the simultaneous inactivation of 
E2f4 and E2f5 in mice results in neonatal lethality (Gaubatz et al., 2000).
A third group of the E2F family is defined by E2F6, the most recently 
identified member. Residues that are crucial for the DNA-binding and 
dimerization activities of the other E2Fs are conserved in E2F6, but it lacks 
the carboxy-terminal sequences, required for both pocket-protein binding and 
transactivation (Figure A).
Overexpression studies have demonstrated that E2F6 represses E2F- 
responsive genes (Cartwright et al., 1998; Gaubatz et al., 1998). It can behave 
as a dominant negative inhibitor through competition with other E2F family 
members (Trimarchi et al., 1998). A complex that contains E2F6, polycomb 
proteins (PcG) and chromatin modifiers has been shown to occupy target 
promoters in GO (Ogawa et al., 2002). Thus, it was suggested that one function 
of E2F6 is to inactivate E2F-dependent genes in quiescent cells. E2F6 
associates with many PcG proteins in vivo, including RYBP, Bm il, MEL-18, 
M phl and Ringl (Trimarchi et al., 2001). PcG proteins form large multimeric 
complexes needed to maintain stable transcriptional repression of Hox genes 
that are expressed along the antero-posterior axis in the vertebrate embryo. In 
addition to this function, PcG proteins also display other activities, for 
example Bmil is a critical regulator of proliferation, senescence and apoptosis 
(Jacobs et al., 1999).
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E2f6 KO mice are viable and healthy, however they appear to be defective in 
spermatogenesis and, similarly to PcG mutant mice, they display homeotic 
transformations of their axial skeleton.
E2F AND CELL PROLIFERATION
Progression through cell-cycle phases is controlled by the sequential activation 
of the cyclin-dependent kinases CDK4/6, CDK2 and CDC2. Their activity is 
regulated by various mechanisms, including the synthesis and binding of a 
specific regulatory subunit (cyclin), both inhibitory and activating 
phosphorylation events, and the association/dissociation of inhibitory 
molecules called CDK inhibitors (GDIs). There are two families of GDIs: 
pl6INK4a, pl5INK4b, pl8INK4c, pl9INK4d belong to the INK4a family; the 
GIP/KIP family includes p21, p27, p57 (Sherr and Weber, 2000) (Figure B).
pl5/pI6  p21
p l8 /p l9  p27/p57
GDK4/6 GDK2 GDK2 
GycIinD 1/2/3 GyclinE Gy d in  A
GDG2 GDG2 
GyclinA GyclinB
V V V V V
01 s 02 M
Restriction point
Figure B - The mammalian cell cycle.
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In mammalian cells, proliferation control is mainly achieved in the G l phase 
of the cell cycle. After G l, cells become independent of extracellular signals 
and progress through the cell cycle to the next G l. The D-type G l cyclins, 
together with their associated kinases, CDK4 and CDK6, initiate the 
phosphorylation of pRB family members, inactivating their capacity to 
interact with the E2F transcription factors. This phosphorylation allows the 
accumulation of E2F1, E2F2, and E2F3 that activate the transcription of a 
large number of genes (Dyson, 1998; Harbour and Dean, 2000; Nevins, 1998). 
These include cell-cycle regulators, such as cyclin E, cyclin A, CDC2, 
CDC25, Myc, B-Myb, and products that are required for DNA replication, 
such as large subunit of DNA polymerase a , ribonucleotide reductase, 
proliferating nuclear antigen (PCNA) and minichromosome maintenance 
proteins (MCMs) (Helin, 1998). In addition, phosphorylation of pRB and p i 30 
disrupts complexes with E2F4 and E2F5 found in quiescent cells that function 
as transcriptional repressors of S phase genes as well as the genes encoding 
the E2F1, E2F2, and E2F3 proteins. E2F activation of cyclin E/CDK2 kinase 
activity leads to the further phosphorylation and inactivation of pRB, thus 
enhancing E2F activity and increasing the accumulation of cyclin E/CDK2.
One of the most striking properties of E2F proteins is their ability to drive 
cells into S phase. This is central to most models of E2F function and was first 
shown for E2F1 (Johnson et al., 1993). E2F1 overexpression overrides many
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different types of cell cycle arrest (including the effects of p l6 , p21, p27, y- 
irradiation, TGF(3 and dominant negative CDK2) and is able to drive 
immortalized quiescent cells into S phase (DeGregori et ah, 1995a; Johnson et 
ah, 1993; Lukas et ah, 1996; Mann and Jones, 1996; Schwarz et ah, 1995). 
The proportion of cells in G  ^ is increased by the overexpression of dominant 
negative mutants of E2F1, DPI and DP2 (Wu et ah, 1996) or by the 
expression of com petitor RNA m olecules (Ishizaki et ah, 1996). 
Microinjection of antibodies to E2F3 reduces the percentage of REF52 cells 
entering S phase (Leone et ah, 1998) and E2/3 deficient MEFs have low levels 
of proliferation and deregulation in the expression of E2F responsive genes 
(Humbert et ah, 2000b). Finally, the combined mutation of E2/1, E2/2 and 
E2J3 blocks cellular proliferation (Wu et ah, 2001). Instead, E2F4 and E2F5 
are fully dispensable for cellular proliferation (Humbert et ah, 2000a; 
Lindeman et ah, 1998; Rempel et ah, 2000).
A further indication comes from the Drosophila genome that encodes just two 
E2F genes, de2fl and de2j2, dE2Fl is a potent activator of transcription: loss 
of de2fl results in the reduced expression of E2F-regulated genes (Frolov et 
ah, 2001) and in low levels of DNA synthesis (Duronio et ah, 1995). In 
contrast, dE2F2 represses the transcription of E2F reporters and the loss of 
de2j2 function results in increased gene expression. In the absence of both 
proteins, larval cell proliferation is relatively normal.
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E2F AND THE pRB PATHWAY
A conserved domain near the carboxyl terminus of the E2F proteins mediates 
binding to pRB-family members (Helin et al., 1993a). This binding domain is 
embedded in the transactivation domain of the E2F subunit.
The retinoblastoma gene encodes a 928-amino acid phosphoprotein. pRB 
contains several functional domains. Domains A and B interact with each 
other along an extended interdomain interface to form the central “pocket” 
which is critical to the tumour suppressor function of pRB (Qin et al., 1992). 
Viral oncoproteins and a number of endogenous pRB-binding proteins contain 
an LXCXE motif that allows them to bind pRB (Lee et al., 1998). The binding 
site for LXCXE is in domain B. Domain A allows domain B to assume an 
active conformation. E2Fs do not contain an LXCXE and thus bind pRB at a 
distinct site with points of contact in both the pocket and in the carboxy- 
terminal region. This allows E2F to recruit to a promoter the complexes 
containing pRB and other proteins, such as those with the LXCXE motif. 
Another functional domain of pRB is located within the carboxy-terminal 
region. This region contains binding sites for the c-Abl tyrosine kinase and 
MDM2, which appear to be distinct from the E2F site in the carboxy-terminal 
region (Xiao et al., 1995).
pRB is phosphorylated and dephosphorylated during the cell cycle: the 
hyperphosphorylated (inactive) form predominates in proliferating cells,
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whereas the hypophosphorylated (active) form is generally more abundant in 
quiescent or differentiating cells (Buchkovich et al., 1989; Chen et al., 1989; 
DeCaprio et al., 1992). Cell cycle progression normally occurs when pRB is 
inactivated by phosphorylation catalyzed by CDKs in complex with their 
cyclin partners. Three different cyclin/CDK complexes have been suggested to 
phosphorylate pRB during the cell cycle. Cyclin D-CDK4/6 phosphorylates 
pRB early in G l, cyclin E-CDK2 phosphorylates the protein near the end of 
G l, and cyclin A-CDK2 may maintain phosphorylation of pRB during S 
phase (Sherr, 1996).
pRB regulates E2F-responsive genes through two distinct mechanisms. First, 
pRB binds to an 18-amino-acid motif within the transactivation domain of 
E2F, thereby blocking the ability of E2F to recruit the transcriptional 
machinery (Helin et al., 1993a). Second, the pRB-E2F complex retains its 
ability to bind to the promoters of E2F responsive genes and can enlist 
chromatin remodeling enzymes and lead to transcriptional repression (Zhang 
and Dean, 2001). These factors include histone deacetylase enzymes (HDACs) 
which remove acetyl groups from the tails of core histones in the nucleosome 
and the ATP-dependent remodeling complex SWI/SNF (the human SWI/SNF 
ATPases are BRG l and hBRM) (Harbour and Dean, 2000). pRB-E2F 
complexes can also recruit the histone methyltransferase SUV39H1 creating a 
high-affinity binding site for the heterochromatin protein 1 (H Pl) on E2F- 
responsive promoters (Nielsen et al., 2001) (Figure C).
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Figure C -  pRB controls E2F activity.
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Deregulation of the pl6INK4a/CDK4/cyclin D/pRB pathway is a prerequisite 
for oncogenesis. Although mutations in pRB and its upstream regulators 
(Figure C) are frequently found in human tumours, intragenic mutations in the 
genes encoding the E2F and DP transcription factors have not been isolated 
(Bartek et al., 1996; Weinberg, 1995). One reason for this may be that 
mutations in the pRB pathway are epistatic to E2F1 mutations. Indeed, most 
tumour-derived pRB mutants show a defect in their ability to regulate E2F 
function. However, low penetrance alleles of pRB  have been described which 
seldom lead to tumour development, despite loss of E2F binding function. 
Conversely, N-terminal mutants of pRB with preserved E2F binding 
capability are unable to fully rescue pRB deficiency in mice and give rise to
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human tumours, again with low penetrance (Riley et al., 1997). Therefore, loss 
of pRB function and gain of E2F function do not have equivalent 
consequences.
Oncogenes
INK4a
Mitogens
Ras
i
CycD/CDK4
T
p27kipi
T-Ag
ElA
E7
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pRB E2F
T
CycE/CDK2
proliferation
or
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Figure D - The pRB pathway.
Two other pocket proteins, p l07 and pl30, are homologous with pRB within 
the pocket, and they also bind viral oncoproteins and E2F. All three pocket 
proteins interact with histone deacetylases (HDACs) in vivo, and can therefore 
both inhibit transcriptional activation and mediate active repression of E2F 
responsive genes. They all arrest cells in G1 when overexpressed. The pocket 
proteins have also unique properties. First, they bind to different members of 
the E2F family in vivo. pRB can bind E 2 F 1 ^ , whereas pl07 and pl30 bind to 
E2F4 and E2F5 (Nevins, 1998). Second, these associations occur at distinct 
stages of the cell cycle: whereas pl30/E2F complexes are found mainly in 
quiescent or differentiated cells (pl30/E2F4 is the most abundant complex in 
GO), pRB binds to E2F in both quiescent and actively dividing cells, and p i07
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is mostly associated with E2F during S phase, but can also be found in G l.
The rare incidence of p l0 7  and/or p i 30 mutations in human tumours indicates 
that p i 07 and p i 30, unlike pRB, do not function as tumour suppressors. 
Mutant mice models have revealed dramatic differences in the biological roles 
of the pocket proteins (Mulligan and Jacks, 1998).
jR6-deficient embryos die at midgestation with inefficient erythropoiesis as 
well as abnormal cell cycle entry and cell death in the liver, lens and nervous 
system (Clarke et al., 1992; Jacks et al., 1992; Lee et al., 1992). These defects 
can be partially rescued through combined mutation of E 2fl, suggesting that 
increased E2F activity is responsible for many of the effects o f Rb deficiency 
in embryogenesis (Tsai et al., 1998). However recent studies have observed 
that Rb-/- mice show dramatic defects in the labyrinth layer of the placenta, 
characterized by marked hyperplasia of trophoblast cells and severe dysplasia 
of the labyrinth architecture, associated with a decrease in placental transport 
function (Wu et al., 2003). When supplied with a normal placenta, either via 
tetraploid aggregation or by genetic approaches, Rb-/- embryos are able to 
survive to full term, suggesting that an abnormal placenta is the primary cause 
for the embryonic lethality of Rb-/- animals. Like in Rb knockout embryos, 
rescued animals show a marked increase in DNA replication and cell division 
in the CNS. In sharp contrast, the typical widespread neuronal apoptosis is 
absent in Rb-deficient embryos reconstituted with a normal placenta. In lens 
fiber cells, however, the inappropriate proliferation and apoptosis that is
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normally observed in Rb-/- embryos persists (de Bruin et al., 2003b). Rescued 
animals died at birth with severe skeletal muscle defects.
Rb-\-/- mice and chimeric animals made with Rb-/- ES cells develop pituitary 
and thyroid tumours but not retinoblastoma or any of the tumours commonly 
associated with RB  mutation in humans. In contrast, mice that lack p i 07  or 
p l3 0  are viable and tumour free at an age of two years. Analysis of double­
mutant mice has provided evidence for overlapping roles of the three family 
members in mouse development and cell cycle control. Rb-/-, p l07-/-  and Rb- 
/-,p l30-/-  embryos die earlier during mouse development than Rb-/- embryos, 
with more pronounced cell cycle defects and increased cell death (Lee et al., 
1996). However differences in the genetic background of mice have been 
shown to be important determinants of the developmental consequences of the 
genetic loss of p l0 7  and p i 30. On a mixed 129/Sv x C57BL/6 genetic 
background, pl30-/-',p l07-/- mice die just after birth with defects in bone 
formation and abnormalities in chondrocyte proliferation (Cobrinik et al., 
1996). Mice with disruptions in p l0 7  and p i 30 in a BALB/c background have 
more severe phenotypes (LeCouter et al., 1998a; LeCouter et al., 1998b).
The effect of pRB family mutations has also been examined in mouse 
embryonic fibroblasts (MEFs) in culture. Rb-/- and p i 07-/-; p i 30-/- fibroblasts 
(Hurford et al., 1997) each have mild defects in cell cycle regulation and 
show differences in the inappropriate expression of cell cycle regulated genes. 
/?RZ?-deficient MEFs prematurely express both cyclin E  and p l07 , whereas the 
combined mutation of p i  07  and p i 30 causes the inappropriate activation of
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the DHFR, B-myb, cdc2, E2fl, TS, RRM2 and cyclin A2 genes during GO/Gl 
(Mulligan, 1998). In growth-limiting conditions, Rb-I- MEFs enter S phase, 
suggesting that expression of p i07 and p i 30 are not sufficient substitutes for 
pRb in the arrest of G l and in the repression of E2F target genes (Almasan et 
al., 1995). Yet, combined loss of pocket proteins immortalizes MEFs and 
abolishes G l arrest after y-irradiation, contact inhibition or serum starvation, 
demonstrating that they have some overlapping function in vivo (Dannenberg 
et al., 2000; Peeper et al., 2001; Sage et al., 2000).
E2F AND THE p53 PATHW AY
p53  is mutated in more than 50% of human cancers and accumulates in 
response to cellular stress from DNA damage, hypoxia and oncogene 
activation. When stabilized and activated, p53 starts a transcriptional 
programme that can either arrest the cell cycle allowing the repair of damaged 
DNA or commit cell to death (Vogelstein et al., 2000).
For example, p53 levels and activity increase after DNA damage (Figure E), 
in part as a result of de novo phosphorylation and conformational changes. 
Phosphorylation at serine 15 prevents the interaction of p53 with MDM2, 
which mediates p53 export from the nucleus and targets it for ubiquitin- 
mediated proteasome degradation. MDM2 is, in turn, negatively regulated by 
ARE (Sherr and Weber, 2000).
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Figure E -  The p53 pathway.
Oncogenes can also induce p53 (Figure E), leading to increased apoptosis or 
premature senescence (Serrano et al., 1997). The adenovirus E lA  oncoprotein 
induces p53 and promotes apoptosis in primary cells, which is reflected by the 
remarkable ability of E lA  to enhance radio- and chemo-sensitivity (Lowe et 
al., 1993). Although E lA  is a mitogenic oncogene, p53 acts to limit its 
oncogenic potential: p53-deficient primary fibroblasts expressing E lA  are 
resistant to apoptosis and become oncogenically transformed (Lowe et al.,
1994). The ability of E lA  to activate p53 is not unique, as c-Myc activates 
p53 to promote apoptosis and oncogenic RAS induces p53, leading to 
premature senescence (Serrano et al., 1997).
Like p53, ARF is a potent tumour suppressor. As mentioned above, ARF is
induced by oncogenes (de Stanchina et al., 1998; DeGregori et al., 1997;
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Palmero et al., 1998). This results in p53 activation and commits cells that 
have sustained oncogenic damage to either growth arrest or apoptosis. ARF 
provides an important connection between E2F1 and p53. Its expression is 
slightly elevated in Rb-/- cells (de Stanchina et al., 1998), consistent with the 
possibility that A RF  is an E2F responsive gene (DeGregori et al., 1997). 
Indeed, enforced expression of E2F1 induces ARF and conversely, Ar/-null 
cells are resistant to E2F1 induced apoptosis (Bates et al., 1998). The A R F  
transcript derives from the same genomic locus as the pl6INK4a  transcript. 
Even though they share sequences in exons 2 and 3, exon 1 is different and 
causes translation in different reading frames. Consequently, pl6INK4a and 
ARF are unrelated at the protein level (Sherr, 1998). Nevertheless, they both 
can mediate cell cycle arrest. While p l 6-induced cell cycle arrest is dependent 
on functional pRB, ARF-mediated cell cycle arrest depends on functional p53 
(Kamijo et al., 1997). Several observations suggest that ARF may function in 
a genetic and biochemical pathway that involves p53. The consequences of 
deleting p53 and Arfdcco remarkably similar. In either case, the mutant mouse 
develops normally, but is highly predisposed to malignant tumours of a similar 
overall pattern and latency. MEFs null for A r f  or p53  do not undergo 
replicative senescence and can be transformed by RAS alone in the absence of 
an immortalizing oncogene (Harvey and Levine, 1991; Kamijo et al., 1997). 
Established MEF cell lines that lacked A t/preserved p53 function, whereas 
those that retained A r/had sustained p53 mutations. Cells lacking a functional 
p53 gene are resistant to ARF induced cell cycle arrest, impling that p53 acts
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downstream of ARF (Kamijo et al., 1997). Nevertheless, ARF is not the only 
activator upstream of p53: cells lacking ARF have an intact p53 checkpoint in 
response to UV and ionizing radiation. Indeed, p53 is induced upon DNA 
damage via the ATM and ATR protein kinases, directly or indirectly through 
the CHK2 kinase (Hirao et al., 2000). The phosphorylation of p53 by 
ATM/ATR then blocks the ability of MDM2 to target p53 destruction. E2F1 
might also be involved in the DNA-damage-response pathway. Treatment of 
cells with chemotherapeutic agents increases E2F1 protein levels. The 
induction of E2F1 in response to DNA damage similarly involves the 
ATM/ATR kinases (Lin et al., 2001), which phosphorylate and stabilize E2F1, 
inhibiting its degradation. The specificity of ATM and ATR for E2F1, rather 
than other E2F proteins, reflects a unique phosphorylation site within the N- 
terminal domain of E2F1. The upregulation of E2F1 in response to DNA 
damage likely provides a synergistic activation of p53 through the induction of 
ARF  or contributes to p53-independent apoptosis, possibly via p73.
DEREGULATED ACTIVITY OF E2F 
Oncogenic activity ofE2F
The first indications that E2F1 has oncogenic potential come from classical 
oncogene cooperation studies in vitro. E2F1 cooperates with activated RAS in 
soft agar assays and the transformed cells produce tumours in nude mice. This 
effect is more pronounced in cells expressing a pRB-binding deficient 
E2F1/VP16 chimera that retains transactivation activity (Johnson et al., 1994)
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or a point mutant of E2F1 specifically defective in pRB binding (Shan et al., 
1996). This suggests that pRB counteracts the oncogenic effect of E2F1. The 
expression of E2F1-2-3 alone is sufficient to transform NIH3T3 (Xu et al.,
1995). Targeted expression of E2F1 in transgenic mice has demonstrated that 
E2F1 overexpression promotes tumorigenesis in vivo (Pierce et al., 1998). 
Finally, tumours phenotypes resulting from the inactivation of pRB are 
impaired when the mice are backcrossed into an E2fl-/~ background (Tsai et 
al., 1998; Yamasaki et al., 1996), suggesting that tumour growth depend on 
the E2F1 that is released when pRB function is blocked. Free E2F1 may 
become essential for tumour cells by providing them with a proliferative 
advantage when growth factors are limiting.
Surprisingly, E 2fl knockout mice develop a broad spectrum of tumours such 
as lymphomas, lung adenocarcinomas and tumours of the reproductive tract 
(Yamasaki et al., 1996), suggesting that E2F1 behaves also as a tumour 
suppressor.
E2F-induced apoptosis
In addition to inducing proliferation, de-regulated E2F activity can trigger 
apoptosis (Bates et al., 1998; Hsieh et al., 1997; Phillips et al., 1997; Qin et al., 
1994; Shan and Lee, 1994). The E2F1-induced apoptosis is potentiated by the 
presence of wild-type p53. However, both overexpression experiments and 
mutant mouse models indicate that death can be induced through either p53- 
dependent or p53-independent mechanisms (Phillips et al., 1997; Phillips et
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al., 1999). E2F triggers p53-dependent apoptosis through the transcriptional 
activation of ARF, a known E2F-target gene (Bates et al., 1998; DeGregori et 
al., 1997). However, studies of mutant mouse models suggest that E2F can 
induce p53-dependent apoptosis in both embryonic tissues and epithelial brain 
tumours in the absence of ARF (Tolbert et al., 2002). In addition, ectopic 
expression of ARF results in cell cycle arrest rather then apoptosis (Sherr, 
1998). So alternative mechanisms must exist besides ARF for the p53- 
dependent apoptosis.
It is widely believed that loss of pRB results in apoptosis as a consequence of 
higher E2F activity. Rb-deficient mice die in midgestation with widespread 
apoptosis (Clarke et al., 1992; Jacks et al., 1992; Lee et al., 1992), whereas 
embryos that are mutants for both Rb and E2fl show a significant reduction in 
apoptosis and down-regulation of the p53 pathway (Tsai et al., 1998). This 
suggests that the E2fl resulting from loss of pRb function mediates most of 
the p53-dependent apoptosis (Bates et al., 1998), and it could explain why 
E2F1 overexpression alone is not sufficient for tumorigenesis. A direct link 
between E2F-induced apoptosis and the apoptosome has been shown. The 
expression of A P A F l is regulated by E2F and A P A F l is required for E2F- 
induced apoptosis (Moroni et al., 2001). In combination with cytosolic 
cytochrome c and the caspase 9 protease, APAFl forms the apoptosome and 
activates the downstream caspase proteases.
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E2Fs can trigger p53-independent apoptosis, but unlike p53-dependent 
apoptosis, it does not require E2F transactivation and can be triggered by 
expression of the E2F DNA-binding domain alone (Hsieh et al., 1997; Phillips 
et al., 1997). This occurs in functionally RB  negative cells, so the role of the 
E2F DNA-binding domain may be to displace free E2F rather than pRB-E2F 
repressor complexes from promoters. At least two distinct pathways have been 
proposed for the induction of p53-independent apoptosis. These include 
transcriptional activation of the p53 family member, p73  (Irwin et al., 2000; 
Lissy et al., 2000) and a non-transcriptional mechanism that involves 
inhibition of the tumour-necrosis factor receptor (TNFR)-associated survival 
response (Phillips et al., 1999). Both p53 dependent and independent apoptosis 
has been observed in vivo. In the central nervous system (CNS) of Rh-/- mice 
apoptosis is p53-dependent, since cells in the CNS of Rb-/-, p53-/- embryos 
continue to ectopically enter S-phase, but do not die. The apoptosis that occurs 
in the peripheral nervous system (PNS) is p53-independent (Macleod et al.,
1996).
Previous studies have shown that E2F1 is somewhat unique among the E2F 
family members in its ability to trigger apoptosis (DeGregori et al., 1997). 
More recent studies suggest that apoptosis can be triggered by ectopic 
expression of E2F1, E2F2, or E2F3 (Vigo et al., 1999) and that nuclear 
localization and DNA binding are required for the apoptotic activity of the 
E2Fs (Loughran and LaThangue, 2000). Expression of E2F4 at elevated levels 
induces growth arrest and caspase-dependent apoptosis through a mechanism
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distinct from E2F1 (Chang et al., 2000). Mutant mouse embryos that lackpRh, 
and either E2fl or E2f3, show a significant reduction in the levels of apoptosis, 
as well as the number of ectopic S-phase cells relative to those seen in mice 
lacking only pRb (Tsai et al., 1998; Ziebold et al., 2001). Restoration of pRb 
function in extra-embryonic lineages (Wu et al., 2003) is sufficient to rescue 
many of the embryonic defects of pRb knockout fetuses, suggesting that 
inactivation of E2F1 or E2F3 from Rb-/- placental may be sufficient to rescue 
early lethality.
TRANSCRIPTIONAL ACTIVITY OF E2F 
E2F target genes
A role for E2F in the activation of several G l/S transition, S phase and DNA 
replication genes has been well established. Typical targets include those 
encoding cell cycle regulators that trigger S-phase entry (such as cyclin E, c- 
Myb, and CDK2), products involved in the assembly of the pre-replication 
complex at origins of replication (such as ORC proteins, MCMs and CDC6), 
and enzymes needed for the direct synthesis of DNA (ribonucleotide 
reductase, thymidine synthase and DNA polymerase a ) . (Helin, 1998; 
Nevins, 1998).
E2F regulates the expression of several genes with mitotic functions. For 
example, cyclin B1 and B2, Bubl and cdc2, genes involved in the progression 
through M-phase, and RanBMP, a gene required for centrosome duplication 
(Ishida et al., 2001; Müller et al., 2001). In the survey of promoters that co-
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immunoprecipitate with E2F1 or E2F4 (Ren et al., 2002) were found not only 
cdc2 and cdc25a, but also promoter fragments for genes with a variety of M- 
phase functions, including smc2 and smc4 (chromosome condensation), bub3 
and mad2 (spindle checkpoints), centromere protein and securin (chromosome 
segregation). Some of these genes are known to induce aberrant spindle 
behavior when overexpressed, and, potentially, misexpression of these targets 
may contribute to the chromosomal instability observed in transformed cells. 
Continual E2F activity during S phase allows the maintenance of high levels 
of cyclinA-CDK2 that are responsible for the inactivation of the anaphase 
promoting complex (APC). APC is a ubiquitin ligase that targets cyclin B1 for 
degradation. By keeping the APC inactive, E2F allows the accumulation of 
cyclin B1 at the end of S phase that is required for the progression of mitosis 
(Lukas et al., 1999).
Recent studies suggest that E2F1 has a physiological role in DNA-damage 
responses. Upon DNA damage, E2F1 is directly phosphorylated and stabilized 
by the ataxia-telangiectasia protein (ATM), a key player of the cellular 
response to DNA damage (Lin et al., 2001).
E2F1 is known to downregulate the expression of anti-apoptotic factors 
(Phillips et al., 1999), and several pro-apoptotic genes have been proposed to 
be induced by E2F1, including Apaf-1, Caspase 3 and Caspase 7 (Müller et 
al., 2001). E2F1 expression leads to stabilization of p53, an effect that was 
thought to be mediated by transcriptional upregulation of p l4 /p l9 ^ ^ .  
Mutation in the p i 9^^, however, failed to suppress the neuronal apoptosis
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phenotype of mouse pRb  mutant embryos (Tsai et al., 2002), indicating that 
other connections to p53 must also exist. E2F proteins are present at the 
promoters of chkl (Ren et al., 2002), which encodes a kinase that is activate 
by ATM and required for the cellular response to DNA damage, and p53. 
Other groups found that the transcription of p73, a p53 homologue, is E2F- 
inducible, and showed that the levels of p73 can influence rates of E2F1- 
induced apoptosis (Irwin et al., 2000; Lissy et al., 2000; Stiewe and Putzer, 
2000).
Xenopus and Drosophila E2F activity are required for axis determination in 
early development (Duronio et al., 1995; Suzuki and Hemmati-Brivanlou, 
2000). It has been suggested that the E2Fs regulate axis determination through 
homeobox-containing proteins in Xenopus (Suzuki and Hemmati-Brivanlou, 
2000) and an EGF-receptor ligand, Gurken in Drosophila (Myster et al., 
2000). In mammals, the E2Fs regulate the expression of several proteins that 
are involved in early development, including homeobox proteins, transcription 
factors involved in cell fate decision, a number of proteins that determine 
homeotic gene transcription, and signaling pathways such as the TGF(3 and 
Wnt pathways that are essential for early development. Several PcG genes 
were identified, like Enhancer of Zeste 2 (EZH2), Embryonic Ectoderm 
Development protein (EED) and Homolog of Polyhomeotic {EDR2/HPH2) 
(Müller et al., 2001).
The pRB/E2F pathway is known to be central in the regulation of various 
types of cellular differentiation (Lipinski and Jacks, 1999). For example, pRB
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is required for erythroid, neuronal, eye, muscle, and adipocyte differentiaton 
(Lipinski and Jacks, 1999). Both p l07  and p l30  are required for normal 
endochondrial bone development (Cobrinik et al., 1996). In addition, E2F4 is 
known to contribute to hematopoetic lineage and to craniofacial development 
(Humbert et al., 2000a; Rempel et al., 2000), whereas loss of E2f5 leads to 
overproduction of cerebrospinal fluid and to hydrocephalus (Lindeman et al., 
1998). In my laboratory (Müller et al., 2001) a number of transcription factors 
that are involved in cell fate decisions, such as Hairy/enhancer of split related 
{HEYl), Paired-like homeodomain {PTXl), ID4, MAF family members, and 
Sox9 were found. In addition, E2F activation led to a dramatic change in the 
expression of genes in the TGFp pathway.
In summary, the E2F-regulated genes code for proteins whose activity control 
cell cycle progression, proliferation, apoptosis, differentiation, and 
development.
E2F-mediated repression
The analysis of E2F-responsive genes shows that E2F-DP-pocket-protein 
complexes are involved in the repression of E2F target genes (Hateboer et al., 
1998; lavarone and Massague, 1999; Johnson et al., 1994). Mutation of the 
E2F-binding sites within known E2F-responsive promoters (B-Myb, CDC2, 
E2F1, cyclin E, CDC25A, CDC6 and ORCl) leads to increased transcription 
after serum starvation or treatment with TGF(3. In some cases, deacetylase 
activity is required for repression of transcription. In vivo footprinting studies
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with the B-Myb, cyclin A  and CDC2 promoters detected E2F site occupancy in 
quiescent cells only in the repressed state (Zwicker and Muller, 1997), while 
the promoters are unoccupied during the G l/S transition when the genes are 
actively transcribed. These data have led to the model that E2F can participate 
in repression of transcription by tethering pocket proteins to E2F target 
promoters, which in turn recruit chromatin remodeling factors including 
histone deacetylases (HDACs), members of the ATP-dependent chromatin 
remodeling complex SWI/SNF, DNA methyltransferase 1 (DMNTl) and the 
histone-methyltransferase SUV39H1 (Figure C). For a number of genes, the 
replacement of endogenous E2F by dominant negative E2F1 leads to 
activation of transcription, meaning that the endogenous E2F complexes 
normally repress the expression of the gene. Overexpression of this dominant 
negative form of E2F1 (which can bind to DNA, but cannot transactivate or 
bind to pocket proteins) compromises the ability of cells to arrest in G l in 
response to pl6INK4a, TGFp and contact inhibition (Zhang et al., 1999). In 
another study the same E2F mutant results in immortalization, bypasses 
RASV12 induced senescence and rescues ARF- and p53- induced cell cycle 
arrest (Rowland et al., 2002). This has been interpreted as a result of 
transcriptional derepression of E2F target genes, whose downregulation is 
critical for the establishment of G l arrest.
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E2F-mediated transactivation
A number of experiments support the view that E2F is a transcriptional 
activator. E2F proteins activate transcription of simple reporter constructs with 
multiple E2F-binding sites (Helin et al., 1992; Shan et al., 1992), they contain 
conserved domains that activate transcription when transferred to other DNA 
binding domains (Kaelin et al., 1992) and there is a strong correlation between 
the ability of E2F to activate transcription and to drive cell cycle progression 
(Johnson et al., 1993; Qin et al., 1995; Shan and Lee, 1994). Viral 
oncoproteins target the pocket proteins to release free, transcriptionally active 
E2F rather than to displace E2F repressor complexes. In vivo footprinting 
studies have detected E2F site occupancy in phases of the cell cycle when 
pocket proteins are largely inactivated (Hateboer et al., 1998). Finally, E2F- 
DNA binding activity is downregulated in S phase when DP is phosphorilated 
by cyclin A-CDK2 and E2Fs are degraded (Krek et al., 1995). The loss of 
E2F-DNA binding activity correlates with decreased transcriptional activity of 
a number of E2F target genes at this point of the cell cycle, such as cyclin E. 
How E2F activates transcription is not known. At least three different 
mechanisms have been suggested. In vitro, E2F1 can bind to TBP (TATA 
binding protein) (Hagemeier et al., 1993). Biochemical studies show that the 
transcriptional activation domain of E2F1 can interact with CBP (CREB 
binding protein), potentially recruiting histone acetylase activity (HAT) to the 
promoter (Tronche et al., 1996) and the transcriptional activity of E2F1 is 
potentiated by the overexpression of CBP. Alternatively, the ability of E2F
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complexes to bend DNA may be important for transcriptional activation 
(Cress and Nevins, 1996).
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MA TERIALS AND METHODS
CLONING TECNIQUES
Agarose gel electrophoresis. DNA samples were loaded on 1% agarose gels 
along with DNA markers. Gels were made in TAB (Tris-acetate-EDTA) or 
TBE (Tris-borate-EDTA) buffer containing 0.3 p-g/ml ethidium bromide and 
run at 80V until desired separation was achieved. DNA bands were visualized 
under a UV lamp.
M inipreps. Cells picked from individual transformed colonies were used to 
inoculate 2 ml 2xLB (containing ampicillin at 25 (xg/ml) and grown overnight 
at 37°C. 1ml of cells was taken from each tube and pelleted for 4 min at 14000 
rpm, resuspended in 100 p,l cold solution 1 (50 mM Glucose, 25 mM Tris-HCl 
pH 8,10 mM EDTA pH 8), vortexed and incubated at room temperature for 5 
min. 200 \x\ o f solution 2 (0.2 N NaOH, 1% SDS) was added and the tubes 
incubated on ice for 5 min. Following the addition of 150 [xl 3M potassium 
acetate, pH 4.8 (solution 3) the tubes were incubated on ice for a further 5 min 
and then centrifuged at 14000 rpm for 5 min. The supernatants were retained 
and 400 fxl of a 1:1 mix of phenol: chloroform was added to each. After 
vortexing, the mixtures were separated by centrifugation at 14000 rpm for 2 
min. The aqueous layers were removed to fresh tubes and the DNA was 
ethanol precipitated. Pellets were washed in 70% ethanol and then dried under
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vacuum. The DNA was resuspended in 5 fxl TE which contained 0.1 fxg/ml 
RNase A (Boehringer Mannheim).
Diagnostic DNA restriction. Between 1-3 fxg DNA was digested for 2 hours 
at 37°C with 10 units o f restriction enzyme (New England Biolabs). For 
digestion, the volume was made up to 20 fxl with the appropriate buffer and 
ddH20.
Large scale plasmid preps. Cells containing transfected DNA were expanded 
into 500 ml cultures overnight. Plasmid DNA was isolated from these cells 
using the Qiagen Maxi-prep kit according to the manufacturer’s instructions.
Transformation o f competent cells. Fresh competent cells (Invitrogen) were 
thawed on ice prior to the addition of 1-2 \il of plasmid DNA in 50 fxl o f cells. 
Either water or cut plasmid was included in one transformation as a negative 
control to determine transformation efficiency. Cells were incubated with 
DNA on ice for 30 min and then subjected to a heat shock for 1 min at 42°C. 
The cells were then returned to ice for 2 min and then at 37°C for further 30 
min before plating onto ampicillin plates. Two plates for each reaction were 
used, one treated with 5 \xl of the transformed bacterial cells and the remainder 
plated on the other. Plates were incubated overnight at 37°C.
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Site directed mutagenesis. Site directed mutagenesis was performed using the 
Quick Change mutagenesis kit (Stratagene), following m anufacturer’s 
instructions. Briefly, a sense and an antisense oligo of about 30 nucleotides 
each, carrying the desired mutation, were generated and used in a PCR 
reaction using the wild type construct (20 ng). PCR was performed using the 
Turbo Pfu polymerase, to reduce the chance of introducing unwanted 
mutations. After amplification, 1 pi o f Dpnl restriction enzyme, which 
selectively cuts methylated DNA at the GATC sequence, was added to digest 
the wild type construct. After one-hour incubation at 37°C, the PCR product 
was used to transform competent Escherichia Coli cells and single colonies 
were sequenced for the presence of the desired mutation and the absence of 
other, unwanted, base changes. For the generation of the pCMVDPl and 
pBabeMYDPl point mutants the following oligos were synthesized: 5'-GAA 
TGG CAA GGG CTT ACG GCA TTT CTC-3' as forward primer and 5'- 
GAG AAA TGC CGT AAG CGC TTG CCA TTC-3' as reverse primer. This 
results in a silent mutation of DPI in the target sequence for the siRNA. For 
the amplification step, 16 PCR cycles were performed with a dénaturation step 
of 30” at 95°C followed by an annealing step of 1’ at 55°C and an extension 
step of 20’ at 68°C.
PLASM IDS
pC M V E 2Fl, pCM VE132, pC M V E 2F l(l-374), pC M V ElA 12S and 
pBabePuroHAER-E2Fl were described previously (Fattaey et al., 1993; Helin
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et al., 1993a; Helin et al., 1993b; Vigo et al., 1999). I generated 
pBabeHygro2HA-BM Il by subcloning the Notl/X hol fragment o f the 
pMT2HA-BMIl (a gift of M. van Lohuizen) into pBabehygro2. L. Laimins 
provided pCB6-E6, and S. Polo provided pCMVMDM2. pCMVDPl was 
described in (Helin et al., 1993b). pRetroSUPER-DP 1 was generated by 
annealing of forward primer (5’GATCCCCTGGCAAGGGCCTACGGCA 
TTTCAAGAGAATGCCGTAGGCCCTTGCCATTTTTGGAAA3 ’) and 
reverse primer (5’AGCTTTTCCAAAAATGGCAAGGGCCTACGGCATT 
C T C T T G A A A T G C C G T A G G C C C T T G C C A G G G 3’). In bold is the 
sequence of siRNA for DPI respectively in the sense and anti-sense 
orientation. The annealed oligos were ligated into pRetroSUPER vector 
(Brummelkamp et al., 2002a; Brummelkamp et al., 2002b).
PRIMARY MOUSE EMBRYONIC FIBROBLASTS
C. Sherr kindly provided Arf^" mice (Kamijo et al., 1997). T. Jacks kindly 
provided Rbl^^" (Jacks et al., 1992), Trp53^^' (Jacks et al., 1994) and Cdknla^^" 
(Brugarolas et al., 1995) mice. All mice were of a mixed C57BL/6-129/Sv 
genetic background. For preparation of primary mouse embryo fibroblasts 
(PMEF) we set up matings between heterozygous parents. We considered the 
morning a vaginal plug was observed as d E0.5. PMEFs were established from 
12.5 d embryos. Embryos were harvested, the brain and internal organs were 
removed and the carcasses were minced and incubated with trypsin for 30-45 
min at 37°C. Tissue culture media was added to the cell suspension and the
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cells were further disaggregated. Genotyping was done by PCR. We 
considered plating after disaggregation of embryos as passage 1. PMEFs were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% 
Fetal Bovine Serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin G, 100 
pg/ml streptomycin, and incubated in a humidified chamber at 37°C, 9% CO2.
CELL CULTURE
We maintained WI38 human fibroblasts in DMEM supplemented with 10% 
North American FBS, penicillin/streptomycin and glutamine, in a humidified 
chamber at 37°C, 5% CO2. We generated ER-E2F1 pools by infecting early 
passage (6-7) WI38 cells with retroviruses produced in Phoenix cells 
transfected with pBabePuroHAER-E2Fl (Vigo et al., 1999). To induce 
activation of the ER-E2F1 fusion protein, we treated cells for 24 h with 4- 
hydroxytamoxifen (OHT, 600 nM) after 72 h o f starvation in DMEM without 
serum.
We maintained NIH3T3 in DMEM supplemented with 10% Calf Serum 
Colorado, penicillin/streptomycin and glutamine, at 37°C, 5% CO2. We 
generated ER-E2F1 and ER-E2F1(132) expressing NIH3T3 cells in the same 
way as WI38 cells. NIH3T3 were starved in 0,1% serum for 24 hours.
HeLa, U20S and SA0S2 cells were cultured in DMEM supplemented with 
10% South American FBS, VA13 and IMR90 fibroblasts in 10% North 
American FBS.
38
TRANSFECTIONS
For transfection using the calcium phosphate procedure, 10-15 pg DNA was 
diluted in 439 pi of ddH20 , 61 pi of 2 M CaCl2 were added and the solution 
was added, drop-wise, to 500 pi of 2XHBS. After 15 min incubation, the 
precipitate was added to cells plated on 10-cm-dishes and removed after 7 h. 
Transfections using the Lipofectamine (Gibco BRL) method or Fugene 
method were performed following manufacturer’s instructions.
RETROVIRAL INFECTIONS
Retroviruses were produced by transfecting the Phoenix helper cell line 
(plated at a density of 2 million cells per 10-cm-diameter dish two days 
before) with 10 pg o f DNA. Supernatants were collected 48 h after 
transfection, filtered (0.45 pm), and used to infect WI38 cells. The viral 
supernatant was left on the cells for 3 h, and the procedure was repeated twice 
to increase the efficiency of infection. Two days after infection, the target cell 
cultures were split and puromycine-resistant cells were selected in medium 
supplemented with 1 pg/ml o f puromycine for 4 d. For the experiments 
presented in Fig. 6c, we infected ER-B2F1 expressing WI38 cells with 
pBabeHygro2HA-BMIl and we selected with 100 pg/ml hygromycin B for 10 
days.
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SMALL INTERFERING RNA (siRNA)
From a given cDNA sequence we selected a targeted region 5’-AA(N21) 
(Elbashir et al., 2001) with approximately 50% G/C-content beginning 100 nt 
downstream of the start codon to avoid that regulatory proteins and translation 
initiation complexes could interfere with binding of the siRNP. The selected 
siRNA sequences were blasted (NCBI database) against human EST libraries 
to ensure that only a single gene was targeted. siRNA duplexes were prepared 
by annealing two pairs o f 21-ribonucleotides synthesized by Dharmacon 
Research in annealing buffer (100 mM potassium acetate, 30 mM HEPES- 
KOH pH 7.4, 2 mM magnesium acetate) for 1 min at 90°C, followed by 1 h at 
37°C. Tumour cells were transfected with siRNA duplexes using 
OLIGOFECTAMINE (Invitrogen). For a well of a 12-well plate, we mixed 3 
pi 20 pM siRNA duplex (0.84 pg, 60 pmol) with 50 pi OPTI-MEM 1. In a 
separate tube, we added 3 pi OLIGOFECTAMINE to 12 pi OPTI-MEM 1 and 
we incubated for 7-10 min at room temperature. The two solutions were 
combined, mixed gently by inversion and incubated for 20-25 min at room 
temperature to allow for formation of liposome complexes. Then we added 32 
pi fresh OPTI-MEM 1 to obtain a final volume of 100 pi. The liposome 
complexes were added to cultured cells (50% confluent) seeded the previous 
day in 500 pi of DMEM supplemented with 10% serum without antibiotics. 
The plate was incubated for 1-2-3 days at 37°C. If  necessary, multiple rounds 
of transfection were performed.
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Diploid fibroblasts were transfected using LIPOFECTAMINE 2000 
(Invitrogen). For a well o f a 12-well plate, we mixed 3 pi 20 pM siRNA 
duplex with 50 pi OPTI-MEM 1. In a separate tube, we added 1,5 pi 
OLIGOFECT AMINE to 48,5 pi OPTI-MEM 1 and we incubated for 5 min at 
room temperature. The two solutions were combined, mixed gently by 
inversion and incubated for 20 min at room temperature to allow for formation 
of liposome complexes. The liposome complexes (100 pi) were added to 
cultured cells (80% confluent) seeded the previous day in 500 pi of DMEM 
supplemented with 10% serum without antibiotics.
Immunofluorescence or Western blotting was performed to analyse the 
depletion of the target protein. When no antibodies were available, the level of 
the targeted mRNA was monitored by RT/PCR to control for the specificity of 
the knockdown. As control we transfected cultures with a siRNA duplex 
targeting firefly luciferase (GL2) or buffer, both of which had no detectable 
effect on cell growth or morphology. The human targeted sequences (cDNA) 
were: for DPI (oligo 1: 5’-AATGGCAAGGGCCTACGGCATTT-3% oligo2: 
5’-AAGCAGCTCTTGCCAAAAACC-3 ’), for DP2 (5’-AAA TCC CTG GTG 
CCA AAG GCT TT-3’).
MICROINJECTION EXPERIMENTS
We plated early passage (3-5) PMEFs of the indicated genotypes on 0.5% 
gelatine coated glass coverslips and made them quiescent by cultivation in
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medium containing 0.05% serum for 48-72 h. At the time of microinjection, 
the cells had reached 60 to 80% confluence. We observed similar levels of S 
phase induction in wild type PMEFs prepared from littermates o f p53, 
pl9ARF, p21 and pRb deficient embryos. We prepared PMEFs and tested 
them from at least two independent litters. We observed no significant 
differences between the various litters. We cultured sub-confluent WI38 cells 
and when specified they were starved in serum free medium for 72 h. We 
injected cells with 50 ng/pl o f expression plasmids (unless otherwise 
specified) together with 2 pg/pl rabbit IgG (Jackson Laboratories) directly into 
cell nuclei using a Zeiss automatic injection system. We added BrdU (100 
pM) 4 h after injection and fixed cells 20 h after the addition of BrdU. For 
WI38ER-E2F1, we added 600 nM OHT 6 h after injection, and BrdU 2 h later. 
We fixed cells 16 h after the addition of BrdU. For each experiment, between 
100 and 150 injected cells were counted. The experiments were repeated at 
least three times.
IMMUNOFLUORESCENCE
Cells grown on coverslips (pre-incubated with 0.5% gelatine at 37°C for 30 
min) were fixed in PIPES buffer (PIPES 400 mM pH 6.8, EGTA 500 mM pH 
8, MgCl] IM) containing 4% paraformaldehyde for 10 min, washed in PBS 
(137 mM NaCl, 2.7 mM KCl, 10 mM Na2HP04, 2 mM KH2PO4, pH adjusted 
to 7.4 with KCl) and permeated with 0.1% Triton X-100, 10% goat serum in 
PBS. To detect the injection marker (rabbit IgG), cells were incubated in
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blocking buffer (10% goat serum in PBS) containing FITC-conjugated donkey 
anti-rabbit antibody (Jackson Laboratories). After washing in PBS, cells were 
fixed again in 4% paraformaldehyde. BrdU incorporation was detected by 
incubation in blocking buffer containing anti-BrdU antibody (Beckton 
Dickinson BD347580), 3 mM MgCl2 and 100 U/ml DNase I (Roche). Cells 
were washed extensively before incubation with Cy3-conjugated donkey anti­
mouse IgG (Jackson Laboratories). Nuclei were counterstained with DAPI. 
Some coverslips were stained with antibodies specific for human pl4ARF 
(14P02, NeoMarkers), anti-p53 (DO-1, Santa Cruz), anti-p21 (CP74, kind gift 
o f E. Harlow) or anti-E2Fl (KH20 or KH95 (Helin et al., 1993b)). Cy3- 
conjugated donkey anti-mouse IgG (Amersham) was used as secondary 
antibody.
FLOW CYTOMETRY
At the indicated times, 10  ^ cells per sample were trypsinized, combined with 
any floating cells, pelleted, washed with PBS, repelleted and resuspended in 
PBS. The cells were fixed in cold ethanol (70%, final concentration) and 
stored for at least 30 min at 4°C. The fixed cells were centrifuged, washed 
twice with PBS-BSA 1%, and resuspended in 0.5 ml of PBS containing 
propidium iodide (50 pg/ml) and RNase A (6.25 pg/ml). Samples were 
incubated for 3h at room temperature or overnight at 4°C prior to analysis by 
flow cytometry with a Becton Dickinson FACScan.
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For BrdU FACS, 3X10^ cells were pulsed for 20 min in medium containing 33 
pM BrdU, trypsinized and fixed as above. Cell pellet was incubated in 1 ml of 
denaturating solution (2 M HCl) for 20 min at room temperature. 2ml of 0,1 M 
Sodium Borate pH 8,5 was added and cells were incubated for 2 min at room 
temperature. After two washes in PBS 1% BSA, the pellet was resuspended in 
50 pi anti BrdU (Beckton Dickinson BD347580) diluited 1:5 (1 hour 
incubation at RT), and then in anti-mouse FITC (Sigma) diluited 1:50. Finally 
PI (2,5 pg/ml overnight at 4 C) was added.
WESTERN BLOTTING
Cells were collected in RIPA lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 
1% NP40, 0.5% Sodium Deoxicolate, 0.1% SDS, proteases and phosphatases 
inhibitors). After clearing of the lysates by centrifugation, the protein content 
was determined (Biorad Protein Assay). Equal amounts o f proteins were 
separated on a sodium dodecyl sulfate polyacrylamide gel using an 
appropriate acrylam ide concentration (stock 40%, 30:1 m ix o f 
acrylamide:bisacrylamide) to resolve the molecular weight o f the targeted 
proteins.
Running gel mix: 6% 8% 10% 15%
acrylamide mix (ml) 5 6 7.5 11.25
1.5M Tris pH8.8 (ml) 7.5 7.5 7.5 7.5
Distilled water (ml) 16.9 15.9 14.4 10.65
10% SDS (ml) 0.3 0.3 0.3 0.3
10% APS (ml) 0.3 0.3 0.3 0.3
TEMED (ml) 0.03 0.03 0.03 0.03
TOTAL (ml) 30 30 30 30
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stacking gel mix: acrylamide mix 1.7
IM Tris pH6.8 (ml) 1.25 
Distilled water (ml) 6.8 
10% SDS (ml) 0.1 
10% APS (ml) 0.1 
TEMED (ml) 0.01 
TOTAL (ml) 10
Gel running buffer: Tris-base (pH 8.3) 25 mM
Glycine 192 mM
SDS 0.1%
Proteins were transferred onto nitrocellulose membrane and processed for 
Western Blotting in transfer buffer (20% methanol, 192 mM glicine, 25 mM 
Tris-base) at lOOV for 1 h. We incubated the membrane in 5% milk powder in 
TBST (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.2% Tween-20) for 1 h at 
RT. The blots were probed with the following antibodies: mouse monoclonal 
anti-DP 1 (TED 10), anti-vinculin (Sigma), anti-actin a  (Sigma), anti-pRB 
(PharMingen); rabbit polyclonal anti-CDK2 (Santa Cruz, sc-163). After 
incubation with the appropriate horseradish peroxidase-conjugated secondary 
antibody, the signal was revealed using the ECL (Enhanced 
Chemiluminescence) method (Amersham).
CDK2 KINASE ASS A Y
Infected cultures were lysed by resuspension in lysis buffer (50 mM HEPES 
pH 7.5, 20 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 1 mM DTT, 0.1% Tween 
20, 10% glycerol, 0.1 mM sodium orthovanadate, 1 mM NaF, 1 mM PMSF, 
10 pg/ml of leupeptin, 5 pg/ml of aprotinin, 10 mM (3-glycerophosphate) for 
30 min at 4°C and cleared by centrifugation at 14.000 rpm for 5 min at 4°C.
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Supernatants were assayed for protein concentration (Biorad Protein Assay). 
Protein samples of 0.2-0.5 mg were then precleared and immunoprecipitated 
for 2 h at 4°C with protein A-Sepharose beads (Amersham Pharmacia 
Biotech), precoated with saturating amounts of anti-CDK2 antibody (5 pg of 
SC-163 from Santa Cruz, 1 h of preincubation at 4°C). Immunoprecipitated 
proteins on beads were washed twice with 1 ml of lysis buffer and twice with 
1 ml of wash buffer (50 mM HEPES pH 7.5, 1 mM DTT, 10 mM MgCl], plus 
the protease inhibitors as described above). The beads were resuspended in 
25 pi o f kinase buffer (50 mM HEPES pH 7.4, 10 mM MgCl], 2.5 mM 
EGTA, 1 mM DTT, 10 mM |3-glycerophosphate, 0.1 mM Na3V04 , 1 mM 
NaF, 1 mM PMSF, 10 pg/ml leupeptin, 5 pg/ml aprotinin) containing 1.5 pg 
of histone HI (Roche) as substrate, 20 pM ATP, and 10 pCi of [y-^^P]ATP. 
After incubation for 30 min at 30°C, the samples were boiled in 5X Laemmli 
buffer, separated by SDS-PAGE 12%, and transferred to a nitrocellulose filter.
GEL RETARDATION ASSAY
Double-stranded oligonucleotides containing a wild type E2F DNA binding 
site were end labelled with [y-^^P]ATP by using T4 polynucleotide kinase, 
purified on a 12% polyacrylam mide gel and used as probe. The 
oligonucleotide E2F-sense (the E2F binding site is underlined) was 5 ’- 
ATTTAAGTTTCGCGCCCTTTCTCAA-3 ’. We performed gel retardation 
assays on whole cell extracts (Hepes 20 mM pH 7.5, NaCl 0.42 M, MgCli 1.5 
mM, EDTA 0.2 mM, PMSF 0.5 mM, DTT 0.5 mM, 25% glycerol) from
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interfered HeLa cells by incubating 5-20 pg of cell extract with 1 pg of 
salmon sperm DNA (sonicated to 500 bp single and double stranded) and 5X 
gel shift buffer (Hepes 100 mM pH 7.6, MgCl] 5 mM, EGTA 0.5 mM, NaNg 
0.1%, KCl 200 mM, glycerol 50%) in a 12.5 pi total volume for 10 min at 
room temperature; 1 pi of ^ ^P-labelled oligonucleotide probe (0.1 ng/pl in TE, 
20000 cpm) was then added and the mixture was incubated for a further 20 
min. To control for binding specificity, a 100-fold excess o f unlabelled 
oligonucleotide was added to the binding reaction. The DNA-protein 
complexes were separated on a 4% polyacrilammide gel containing 0.25X 
Tris-borate-EDTA buffer at 4°C. The gel was dried and autoradiography was 
performed.
NORTHERN BLOTTING
WI38-ERE2F1 infected cells were grown with or without 600 nM OHT and/or 
10 pg/ml cycloheximide (CHX) to inhibit protein synthesis. Cells were 
harvested in guanidium thiocianate 4 M, sodium acetate 20 mM pH 5.2, 
Sarkosyl 0.5%, DTT 0.1 mM and lysed by passage through a 20-gauge needle 
eight times. RNA was isolated by CsCl ultracentrifugation method as 
described (Ausubel et al., 1988). Poly A+ RNA was isolated with the Oligotex 
reagents from Quiagen using a batch protocol as described by the 
manufacturer. 1-4 pg of poly A+ RNA were resolved by elettrophoresis on a 
1% agarose gel containing 1.9% formaldehyde and IX MOPS and they were 
transferred to a nylon membrane. We sequentially hybridised the blot with
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^^P-labeled probes (obtained by random primer method) specific for ARF, 
CCNEl, CDKNIA, or GAPDH.
RT-PCR
Total RNA was isolated from cells using the Rneasy extraction kit (Quiagen) 
according to the manufacturer’s instructions. After DNase treatment, 1 pg of 
RNA was used for cDNA synthesis using the Superscript II Reverse 
Transcriptase (GIBCO) following m anufacture’s instruction. PGR was 
performed in an ABI PRISM 7700 Sequence detection system on lOng of 
cDNA, 0.5 pi of a 10 pM primers mix and 2X SYBR Green PGR Master Mix 
(Applied Biosystem) in a 25 pi volume. The reaction was performed at 50°C 
for 2 min, 95°C for 10 min, then 40 cycles at 95°C for 15 sec, 60°C for 1 min. 
We evaluated on agarose gel that the products were of the expected size. 
GAPDH was used as endogenous control. Quantification was expressed 
relative to the untreated control. The following sets o f primers were designed 
using Primer Express Software:
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gene amplicon forward primer reverse primer
CDC6 111 bp AGCACTGGATGITIGCAGGIAG GGGAA1G\GAGQCICAGAAQG
CCNEl 75 bp TOCAGAGOGITGGAlCICKnG GQOGGAAQCAGQ^AGIAmOC
RRM2 113 bp TICAGG\a03GAAIC]GCIG GGCIAAATCXOOCAOCAAG
DHFR 66 bp GAGAACIŒAGGAACiaŒACAAG AGl'lTlAAGGCATG^ TCmGACTICIGG
MCM3 100 bp IGGAGGGCATIGmG^CTAAATG AGAATAACma3CICIAIGGICnC
DPI 71 bp ATITOGGQGATaOjIMCATG IGAAGAOCTIGAGITCIGGGriG
DP2 79 bp AAAGAAATCAAGIGGATIGGOC 10C]GCOCIGCT]OCmTCIC
E2F1 47 bp CAlOXniAaACAGATOGC AACAGCGGITCTIGCIOCAG
TK 51 bp GOCAAAGACAOGGCIACAGC TGGIGnODGGICATGrlGIG
CDC25A 105 bp TGGCATCIGITITCAAIGGC AOGCACXrTIGATGIGGC
GAPD 87 bp GOCICAAGAICAICAGCAAIGC OCACGAmCXAAAGnGKAIGG
Table 1 - Primers used in quantitative PCR.
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RESULTS -  PARTI
AIM
One of the most striking properties of E2F proteins is their ability to drive 
cells into S phase. Short-term expression of E2F1, E2F2, or E2F3 is sufficient 
for the induction of DNA replication in immortalized quiescent rodent 
fibroblasts in the absence of growth factors (Dimri et al., 1994; Johnson et al., 
1993; Lukas et al., 1996; Qin et al., 1994; Shan and Lee, 1994) and requires 
functional DNA binding and transcriptional activity. This is central to most 
models o f E2F function and was first shown for E2F1 (Johnson et al., 1993). 
In immortalized cells, E2F1 overexpression overrides many different types of 
cell cycle arrest, including the effects of p l6 , p21, p27, y-irradiation, TGF(3 
and dominant negative CDK2 (DeGregori et al., 1995b; Lukas et al., 1996; 
Mann and Jones, 1996; Schwarz et al., 1995). The proportion of cells in Gi is 
increased by the overexpression of dominant negative mutants o f E2F1, DPI 
and DP2 (Wu et al., 1996) or by the expression of competitor RNA molecules 
(Ishizaki et al., 1996). Despite this, I observed that overexpression of E2F1 in 
diploid fibroblasts results in cell cycle arrest in G l and apoptosis. Therefore, I 
decided to study the effects of inducible E2F1 activation in primary mouse 
embryo fibroblasts (PMEFs) and non-immortal human diploid fibroblasts 
(WI38), two well-defined cell types that have been widely used to study 
normal cell cycle control since they have not accumulated mutations.
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RESU LTS
E2F1 is not sufficient to induce S phase in diploid fibroblasts 
I microinjected serum-starved PMEFs with expression vectors containing 
E2F1 or adenovirus E1A12S cDNAs driven from the strong cytomegalovirus 
promoter (Fig. \a). The expression of E2F1 from this promoter has been 
reported to induce S phase in quiescent Rati fibroblasts (Lukas et al., 1996). 
In agreement with published results, I observed that E1A12S was sufficient to 
induce S phase in primary rodent cells (Quinlan et al., 1987; Zerler et al., 
1987). This indicates that the cells can enter S phase and are not irreversibly 
blocked by serum starvation. However, the expression of E2F1 in PMEFs did 
not result in an increase in the number of cells entering S phase (Fig. la).
To investigate if the lack of S phase induction by E2F1 was specific for 
primary mouse fibroblasts, I tested whether E2F1 could induce S phase in 
human diploid fibroblasts. I microinjected serum-starved WI38 cells with 
E2F1 or E1A12S expression plasmids and I measured S phase entry. As 
shown in Fig. lb , human diploid fibroblasts expressing E1A12S efficiently 
entered S phase, whereas cells expressing E2F1 were unable to do the same. 
These results indicate that E2F1 is not sufficient to induce S phase in diploid 
fibroblasts, and are in agreement with previous results showing that E2F1 
cannot induce S phase in WI38 cells (Dimri et al., 1994).
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Figure 1 E2F1 is not sufficient to induce S phase in diploid fibroblasts, a, 
BrdU incorporation in wildtype PMEFs. E2F1 or E1A12S expression 
plasmids were micro-injected into serum-starved cells along with IgG as an 
injection marker. Mock-injected or non-injected (Control) cells were negative 
controls. Serum was added for 24 h as a positive control. DNA synthesis was 
assessed by BrdU labeling, b, BrdU incorporation in WI38 fibroblasts. 
Quiescent cells were injected as in (a), c, BrdU incorporation in WI38 ER- 
E2F1 fibroblasts. Quiescent cells were either untreated (Control) or treated 
with OHT or serum for 24 h. Error bars indicate standard deviation of the 
mean of at least three independent experiments.
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My laboratory recently generated cell lines expressing E2F1 fused to the 
estrogen receptor ligand-binding domain (ER) (Moroni et al., 2001; Müller et 
al., 2001; Vigo et al., 1999). The ER-E2F1 fusion protein is expressed at 
relatively low levels as an inactive protein in the cytoplasm. Upon addition of 
the ligand (4-hydroxytamoxifen, OHT), ER-E2F1 translocates to the nucleus 
and transactivates E2F-dependent promoters in a DNA-binding and 
tr ans activation domain dependent manner. The activation of ER-E2F1 
faithfully reproduces all phenotypes associated with expression of native 
E2F1, including induction of S phase and apoptosis in Rati cells (Vigo et al., 
1999) and induction of apoptosis in PMEFs and W138 cells (Moroni et al., 
2001). To understand the biochemical mechanisms that prevent S phase 
induction by E2F1, 1 tested the ability of ER-E2F1 to induce S phase in 
quiescent W138 cells in the absence of serum (Fig. Ic). Consistent with the 
results obtained by microinjection of E2F1 expression plasmid, ER-E2F1 
activation was not sufficient to induce S phase in quiescent normal diploid 
fibroblasts. The expression of ER-E2F1 in the W138 cell line has been shown 
previously (Moroni et al., 2001) and 1 checked it by immunofluorescence (Fig. 
2b). Furthermore, to verify that ER-E2F1 was activated after OHT addition, 1 
examined the expression of two known E2F target genes. Activation of E2F1 
led to a strong increase in CCNEl (Cyclin E l) and ARF  (p i4"^^) expression 
independent of de novo protein synthesis, suggesting that these genes are 
direct targets of E2F1 (Fig. 2a). Activation of E2F1 also induced C D KNIA  
(p21) mRNA levels. However, in contrast to the increased expression of AiRF
53
cl 4 4 4 8 12 h
-  - + + - - CHX
- + - + + + OHT
CCNE1 m
ARF m m
CDKNA1 -
GAPDH m m « # m
-OHT +OHT
DAPI DAPI
Figure 2 Activation o f E2F1 leads to increased levels o f p i  4^^, p53 and p2L  
a. Northern blot analysis of mRNA isolated from WI38 cells expressing ER- 
E2FL Cells were incubated with OHT, cycloheximide (CHX) or both for the 
indicated times. The blot (2 pg of poly A+ RNA) was probed for C C N E l, 
ARE, CDKNIA  or GAPDH expression, b. Immunofluorescence of WI38 ER- 
E2F1 cells. Quiescent cells were incubated for 24 h in the absence or presence 
of OHT. Cells were stained with antibodies specific for E2F1, p i4^^^, p53 or 
p21 on independent coverslips. Nuclei were stained with DAPI.
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and CCNEl, the increase in CDKNIA level was dependent on de novo protein 
synthesis (Fig. 2a\ 1.8-fold induced in lane 2 versus 1.1-fold in lane 4). The 
activation of E2F1 led to increased levels of ARF, p53 and p21 proteins (Fig. 
26).
Since the lack of S phase induction by E2F1 could be due to limiting amounts 
of DPI, the dimerization partner of E2F1, 1 coexpressed DPI with E2F1. 
However, E2F1 did not induce S phase in PMEFs even when co-expressed 
with DPI (Fig. 3).
Loss o f function in the p53 pathway is required for E2F1-induced S phase 
1 next sought to understand the genetic changes that allowed E2F1 to induce S 
phase in immortalized, but not diploid, fibroblasts. p53 is a critical component 
of the arrest pathway activated by a multitude of DNA damaging agents. 
Among other genetic changes, either Arf or Trp53 inactivating mutations are 
the most common single events in the spontaneous conversion of PMEFs into 
continuously growing cell lines (Sherr, 1998). Since ARE is a known E2F1 
target gene (Sherr, 1998), and increased ARF levels induce a p53-mediated 
checkpoint response, 1 investigated whether inactivation of either A r/or Trp53 
would allow E2F1 to induce S phase. 1 prepared PMEFs from A rf- f-  or 
Trp53-f- mouse embryos, 1 serum-starved and microinjected them with E2F1 
or E1A12S expression plasmids. As shown in Fig. 4a, b, expression of E2F1
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Figure 3 The E2F1-DP1 heterodimer does not induce S phase in wildtype 
PM  EE s. Quiescent cells were injected with plasmids expressing E1A12S, 
E2F1, DPI or coinjected with E2F1 and DPI. IgG was used as an injection 
marker. DNA synthesis was assessed by BrdU labeling. Error bars indicate 
standard deviation of the mean of two independent experiments.
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Figure 4 Loss o f function in the ARF-MDM2-p53 pathway allows E2F1- 
induced S-phase in PMEFs. E2F1 induces S phase in Trp53~'~ {a) and ARF^'~ 
{b) PMEFs. Quiescent cells were injected with plasmids expressing E1A12S, 
E2F1 or E2F1 mutants (E132 and 1-374).
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in these cells was as potent as E1A12S at inducing S phase. S phase induction 
was dependent on the DNA binding and transactivation functions of E2F1, 
since DNA binding mutant (E l32) or transactivation mutant (1-374) alleles 
did not induce DNA synthesis. Similarly, in quiescent NIH3T3, which lack 
pl9A R F, the microinjection of E2F1 or E1A12S expression plasmid 
efficiently induced S phase (Fig. 5a, b). Consistent with this, ER-E2F1 
activation was sufficient to induce S phase in quiescent NIH3T3, while ER- 
E132 was not (Fig. 56), although they both localized into the nucleus upon 
OHT addition (Fig. 5c).
I performed several experiments to confirm these results and to understand the 
likely mechanism. First, I coexpressed E2F1 and Bm il. Bm il is involved in 
the regulation of senescence and tumourigenicity (Jacobs et al., 1999; van 
Lohuizen et al., 1998). It was originally identified as a common insertion site 
in Moloney murine leukemia virus (MoMLV)-induced B-cell lymphomas in 
E//-Myc transgenic mice (Adams et al., 1985; van Lohuizen et al., 1991) and 
was only subsequently shown to be a m am m alian PcG protein. 
Overexpression of Bm il in PMEFs results in downregulation of pl6INK4a  
and p l9A R F , causing extension of cellular lifespan, increased proliferation 
and neoplastic transformation in cooperation with oncogenic Ras or Myc 
(Jacobs et al., 1999). Conversely, the absence of Bmil causes de-repression of 
p l6 IN K 4 a  and p  19ARF, leading to premature senescence of PMEFs and 
severe proliferation defects in lymphoid organs and cerebellum. When I co-
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Figure 5 E2F1 induces S phase in NIH3T3 fibroblasts, a, B r d U  
incorporation in NIH3T3. E1A12S, E2F1 or E2F1 mutants (E l32 and 1-374) 
expression plasmids were micro-injected into serum-starved cells along with 
IgG as an injection marker. Mock-injected or non-injected (control) cells 
were negative controls. Serum was added for 24 h as a positive control. DNA 
synthesis was assessed by BrdU labeling, b, BrdU incorporation in NIH3T3 
ER-E2F1 and NIH3T3 ER-E132 fibroblasts. Quiescent cells were either 
untreated (control) or treated with OHT or serum for 24 h. c, 
Immunofluorescence of NIH3T3 ER-E2F1 and NIH3T3 ER-E132. Cells were 
stained with antibodies specific for E2F1. Nuclei were stained with DAPI.
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expressed E2F1 and Bmil in PMEFs, I observed S phase induction (Fig. 6a). 
Since Bmil is a repressor of ARF expression (Jacobs et al., 1999), my result 
is consistent with the notion that ARF is required to block E2F1-induced S 
phase. Second, coexpression of E2F1 and the human papilloma virus E6 
protein or the MDM2 oncoprotein, two proteins that target p53 for 
degradation, induced S phase in serum-starved wildtype PMEFs (Fig. 66). 
This indicates that p53 is needed to block E2F1 induced S phase. Diploid 
human fibroblasts also required the presence of functional ARF and p53, since 
the expression of Bmil (Fig. 6c), E6 (Fig. 6d), or MDM2 (Fig. 6c) in WI38 
cells cooperated with E2F1 to induce S phase entry.
Loss o f p21 allows E2F1 to induce S phase
Activation of p53 in response to unprogrammed growth stimuli results in G l 
and G2 cell cycle arrest, and in some circumstances to apoptosis (Vogelstein 
et al., 2000). The induction of cell cycle arrest is the most common response in 
diploid fibroblasts, and p21^^^^^^^ an inhibitor of cyclin dependent kinases, 
acts as an important effector in the p53-mediated G l arrest induced by DNA 
damaging agents (Vogelstein et al., 2000). For instance, cells lacking 
functional C dknla  (p21) alleles fail to arrest in response to DNA damage 
(Brugarolas et al., 1995) and exhibit reduced growth factor requirements. p21 
and pRb double deficient cells have the ability to grow in soft agar 
(Brugarolas et al., 1998). The analysis of a single p21-/~ clone of human
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Figure 6 Loss o f function in the ARF-MDM2-p53 pathway allows F2F1- 
induced S-phase in Wt PMFFs and WI38 cells, a, b E2F1 cooperates with 
BM Il, E6 or MDM2 to induce S phase in wildtype PMEFs. Quiescent cells 
were injected with E2F1, E6, MDM2 or increasing amounts of BM Il (10-25- 
50 ng ml'^). c, d  E2F1 cooperates with BM Il, E6 or MDM2 to induce S phase 
in WI38 cells. WI38-ER-E2F1 cells were infected with empty vector or 
pBabeHygro2HA-BMIl, made quiescent and incubated with/without OHT. In 
(d) cells were injected with E6 or MDM2 and incubated with/without OHT. 
Error bars indicate standard deviation of the mean of at least three independent 
experiments
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fibroblasts obtained after selection for two independent homologous 
recombination events had led to the conclusion that the loss of p21 gene is 
sufficient to bypass senescence (Brown et al., 1997). Finally, p21 is 
upregulated in association with cell cycle arrest induced by constitutive 
activation of the Ras/Raf/MEK pathway (Serrano et al., 1997).
To understand if p21 was required to prevent E2F1-induced S-phase, PMEFs 
were prepared from C dknla-I-  embryos, serum-starved and microinjected as 
before. As shown in Fig. 7, E2F1 induced S phase in C d k n la - /-  PMEFs. 
These results show that p21 is necessary for sustaining a G l arrest and are 
consistent with the observation that the G l arrest mediated by p21 cannot be 
bypassed either by inactivation of pRB or by overexpression of E2F family 
members (Mann and Jones, 1996).
Loss ofpRB allows E2F1 to induce S phase
Ectopic cell cycle entry and elevated apoptosis levels are apparent in both 
CNS and PNS of R b l- i-  embryos. The inappropriate cell cycle entry is 
accompanied by elevated activity of free E2F proteins and overexpression of 
E2F transcription targets, such as cyclin E (Macleod et al., 1996). 
Additionally, p53 protein levels and p53 DNA binding activity are enhanced 
in the brains of R bl-i-  embryos, leading to increased expression of the p53 
transcriptional target p21. Despite higher levels of p53, inactivation of pRB is 
sufficient for ectopic S phase in Rbl-i- embryos (Macleod et al., 1996).
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Figure 7 Loss o f p21 is required for E2F1-induced S-phase. E2F1 induces S 
phase in Cdknla~^~ PMEFs. Quiescent cells were injected with plasmids 
expressing E1A12S, E2F1 or E2F1 mutants (E l32 and 1-374). Cells injected 
with IgG (Mock) or non-injected (Control) were negative controls. Serum was 
added for 24 h as a positive control. DNA synthesis was assessed by BrdU 
labeling.
Q. 40
-  30
Control Serum Mock E1A E2F1 E132 1-374
Figure 8 Loss o f pRb is required for F2F1-induced S-phase. E2F1 induces S 
phase in Rbl~‘~ PMEFs. Cells were injected as in Fig. 7. Error bars indicate 
standard deviation of the mean of at least three independent experiments.
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To test whether E2F1 was sufficient to induce S phase entry in the absence of 
pRB, PMEFs were prepared from R b l- /-  embryos, serum-starved and 
microinjected with E1A12S and E2F1 expression plasmids. As demonstrated 
in Fig. 8, both E1A12S and E2F1 induced S phase in pRb-deficient PMEFs, 
showing that in addition to causing deregulation of E2F activity, loss o f pRB 
also abrogates the E2F1-induced G l checkpoint. These data suggest that the 
G l/S arrest imposed by E2F expression in Wt PMEFs requires p53-triggered, 
p21-mediated, inhibition of pRB phosphorilation. In addition, the E2F1A^P16 
mutant was unable to release quiescent WI38 cells in S phase, suggesting that 
the interaction between pRB and E2F1 is not required to arrest primary cells in 
G l (Fig. 9). The E2F1A/^P16 chimera cannot interact with pRB since the 
transactivation domain of E2F1 is replaced by the transactivation domain of 
the herpesvirus VP 16, but it is fully transcriptionally active in an E2F 
dependent manner (Johnson et al., 1994). These findings strongly suggest that 
pRB may regulate the G l/S transition through direct binding to other activities 
(proteins) in addition to E2Fs such as ID2, H B Pl, c/EBPa or MyoD 
(Lasorella et al., 2000; Lipinski and Jacks, 1999). I focused my attention on ID 
proteins. They function as dominant negative inhibitors of basic helix-loop- 
helix (bHLH) transcription factors since they lack a DNA binding domain. In 
addition to E2F1, ID2 is the only protein described so far able to disrupt the 
anti-proliferative effect o f pocket proteins, thus allowing cell cycle 
progression (Lasorella et al., 1996). This function correlates with the ability of 
ID2 to associate with hypophosphorylated pocket proteins. To test whether
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Figure 9 pRB and E2F interaction is not required to arrest cells in G L  
WI38-ER-E2F1 and WI38-ER-E2F1/VP16 cells were made quiescent and 
incubated with/without OHT or with serum as positive control for 24h. DNA 
synthesis was assessed by BrdU labeling. Error bars indicate standard 
deviation of the mean of two independent experiments.
.A
Figure 10 ID2 does not cooperate with E2F1 to induce S phase in Wt 
PMEFs. Quiescent cells were injected with plasmids expressing E2F1, ID l, 
ID2 or ID2 mutant (delta 41-71). Non-injected cells (Control) were negative 
control. Serum was added for 24 h as a positive control. DNA synthesis was 
assessed by BrdU labeling.
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pRB could induce G l arrest through direct binding and regulation of some 
bHLH transcription factor in addition to E2F1 binding, I expressed E2F1 in 
quiescent Wt MEFs along with ID2, and, as negative control, ID2A41-71 
mutant, which lacks HLH domain, or ID l, which is not able to disrupt the 
anti-proliferative effect o f pRB. However, none of the constructs was able to 
cooperate with E2F1 to induce S phase (Fig. 10).
Biochemical Mechanism
My data suggest that the G l block imposed by E2F1 overexpression is 
ultimately mediated by pRB, downstream of p21. The role of p21 in this 
pathway raised questions regarding the mechanism. Ample evidence suggests 
that p21 can inhibit both CDK2- and CDK4- associated activity (Gu et al., 
1993; Harper et al., 1993; Xiong et al., 1993). However, after y irradiation, 
p21 allows a pRB-mediated G l arrest (Brugaloras et al., 1999) by inhibiting 
CDK2- and not CDK4- activity. In Cdknla-/- PMEFs, CDK2 activity but not 
CDK4 activity is elevated two to fourfold compared with wildtype cells 
(Brugarolas et al., 1998).
To elucidate the mechanism more fully, I tested the relative kinase activity of 
CDK2 when E2F1 is overexpressed in quiescent Wt or Trp53-I- PMEFs and 
the status of pRB phosphorylation in the same cells. Expression of E2F1 did 
not result in increased level of CDK2 activity in quiescent wildtype PMEFs, 
whereas E2F1 expression increased CDK2 activity in 77pJ3-deficient PMEFs
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Figure 11 Abrogation o f the p53-dependent G1-checkpoint increases Cdkl 
activity and pRb phosphorylation. Wildtype and Trp53 '~ PMEFs were 
infected with pBabePuro HABR-E2F1, made quiescent and incubated 
with/without OHT or serum for 24 h. a, DNA synthesis was assessed by 
BrdU labeling, h. Relative Cdk2 kinase activity was measured using histone 
HI as a substrate, c, Aliquots of cell lysates were run on a 6% SDS-PAGE 
and the level of pRb phosphorylation was assessed by probing the Western 
blot with a specific antibody to pRb (PharMingen). Equal loading was 
confirmed using an antibody to Vinculin (Sigma).
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(Fig. 1 lb). E2F1 expression in p53-deficient, but not in wildtype, PMEFs gave 
hyperphosphorylation of pRB (Fig. 11c).
Cyclin E l and cyclin A2 have been shown (although in tumour cells) to 
override a pRB-mediated G1 block (Hinds et al., 1992; Horton et al., 1995). 
As expected their overexpression along with E2F1, and the consequent 
increase in E2F activity, is sufficient for S phase induction in wildtype PMEFs 
(Fig. 12).
E2F2 and E2F3 induce S phase in ARE- and p53- deficient fibroblasts
E2F2 and E2F3 are highly homologous to E2F1 and, if overexpressed, they 
can induce immortalized quiescent cells to re-enter the cell cycle. When I 
expressed in normal diploid fibroblasts E2F2 and E2F3 they didn’t induce S 
phase. However, they induced S phase in ARF- and p53-deficient fibroblasts 
(Fig. 13a). Consistent with this, I observed that activation of the three E2Fs 
directly induces ARF  expression (Fig. 13b).
Quiescent diploid fibroblasts are not apoptotic in response to E2F1 
I was also interested in studying why E2F1 blocks quiescent primary 
fibroblasts in G l. One possibility is that the G1 arrest observed upon E2F1 
expression in wildtype cells leads to an increase in apoptosis and that cells go 
into S phase because they do not die in a p53-/-, ARF-/- or p21-/- background.
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Figure 12 Coexpression o f Cyclin E l or Cyclin A2 with E2F1 overrides the 
pRb-mediated GI block. Quiescent wildtype PMEFs were injected with 
plasmids expressing E2F1, CDK2, Cyclin A2 (CycA), or Cyclin E l (CycE) 
either alone or in combination. BrdU incorporation was measured 24 h after 
injection. Error bars indicate standard deviation of the mean of two 
independent experiments.
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Figure 13 E2F2 and E2F3 induce S phase when the p53-dependent G l 
checkpoint is disabled, a. Quiescent wildtype, Arf~'~ or Trp53 '' PMEFs were 
injected with plasmids expressing E2F1, E2F2 or E2F3 and BrdU 
incorporation was measured after 24 h. b, Northern blot analysis of mRNA 
isolated from WI38 cells expressing ER-E2F1, ER-E2F2, ER-E2F3 or ER- 
E132. Cells were incubated with OHT, cycloheximide (CHX) or both for the 
indicated times. The blot (2 pig of poly A+ RNA) was probed for pl4A R F 
(short and long exposure in the pannel) or GAPDH expression.
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Another possibility is that the G l block induced by E2F1 protects cells against 
cell death, suggesting an anti-apoptotic role of some pathway-regulated gene. 
In the experiments described above, I didn’t see apoptosis within the 24 hours 
of E2F1 activation. Interestingly, I also observed that quiescent cells 
(independent of the genetic background), didn’t undergo apoptosis within a 72 
hours time period, whereas E2F1 induced very efficient apoptosis in 
asynchronously growing cells even at 24 hours after E2F1 activation (data not 
shown). Therefore, it is unlikely that the inability of E2F1 to induce S phase in 
normal diploid fibroblasts is due to induction of apoptosis. This also suggests 
that E2F1 can induce apoptosis independently of an intact p53 pathway, 
confirming the results of our and other laboratories. Moreover, it shows that 
quiescent cells are less prone to apoptotic signals, maybe because they need to 
be in a phase different from G l to become apoptotic in response to E2F1, 
rather than serum supplies some protein(s) that cooperates with E2F1 to 
induce apoptosis.
DISCUSSION
By analyzing primary cell lines lacking the p53- or pRB-regulated G l 
checkpoint, I have investigated the mechanism required for E2F1 to induce S 
phase (Fig. 14a).
E2F1 is fully competent as a transcriptional activator in diploid cells. Its 
induction in diploid fibroblasts results in the robust activation of several
71
Primary cell: 
E2F t  ------ ► arrestapoptosis
Cell with defect in p53 G1- 
checkpoint or pRB:
E2F t proliferation apoptosis
b
RAS
p16^CDK4:CycD
p R B ^
i
▼
G1
arrest
E 2 F -^
S-phase
entry
ARF MDM2
p21
t
p53
- ^ 1
apoptosis
Figure 14 Model for the regulation o f cell proliferation by the pRB pathway. 
See text for details. Broken arrows signify genetic interactions, whereas non­
broken arrows indicate biochemical and genetic interactions or functions (Gl 
arrest, S phase entry or apoptosis).
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E2F target genes (as shown here for A R F  and CCNEl, and by microarray 
analysis (M, Giro’, H. Müller and K. Helin, unpublished results) in the 
absence of S phase entry. It is unlikely that the inability of E2F1 to induce S 
phase in normal diploid fibroblasts is due to induction of apoptosis. Indeed, I 
did not observe any apoptotic effects of E2F1 in the experiments presented 
here (i.e. 24 h of E2F1 expression). However, apoptosis is induced 36-48 h 
after E2F1 activation in growing diploid mouse and human fibroblasts 
(Moroni et al., 2001). Hence, the consequence of increased E2F1 activity in 
diploid cells is G l arrest or apoptosis, and not DNA replication, unless other 
genetic alterations occur. In contrast, E2F1 efficiently induced DNA 
replication in cells that are impaired in the p53- or pRB-mediated G l 
checkpoint.
My results are consistent with a model (Fig. 146) whereby increased E2F 
activity results in direct activation of A R F  transcription, and subsequent 
upregulation of p53 and p21 levels. The increased levels of p21 in diploid 
fibroblasts appears necessary to block cells in G l since C d kn la -/-  PMEFs 
efficiently entered S phase after E2F1 activation.
I have performed several experiments to test the validity of the model. First, I 
have shown that expression of E2F1 did not result in increased level of CDK2 
activity in quiescent wildtype PMEFs, whereas E2F1 activity resulted in 
increased CDK2 activity in p53-deficient PMEFs (Fig. 116). Second, E2F1
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expression in p53-deficient, but not in wildtype, PMEFs resulted in 
hyperphosphorylation of pRB (Fig. 11c). Third, I have shown that increased 
CDK2 activity is sufficient to cooperate with E2F1 in inducing S phase in 
wildtype PMEFs (Fig. 11a). These observations suggest that p21 imposes G l 
arrest by inhibiting CDK2 activity and by preventing inactivation of the 
growth suppressive properties of pRB tumour suppressor.
It has been shown that expression of E2F1 is sufficient to induce DNA 
synthesis in immortalized REF52 cells (Johnson et al., 1993), even though 
these cells appear to contain functional ARF and p53. REF52 cells may 
contain hitherto unidentified genetic alterations that contribute to 
immortalization and allow the cells to escape the E2F1-induced G l 
checkpoint.
My results are in accordance with previous findings that E2F1 does not induce 
S phase in WI38 cells (Dimri et al., 1994), and that short-term activation of 
E2F1 in proliferating WI38 cells induces Gl arrest (M. Lomazzi, M.C. Moroni 
and K. Helin, unpublished results). In contrast to the work of Dimri and 
colleagues (Dimri et al., 1994), who found that E2F1 was unable to induce S 
phase in NIH3T3 cells that lack pl9ARF, I have shown that expression of 
E2F1 or activation of ER-E2F1 efficiently induced S phase in NIH3T3 cells 
(Fig. 5). The reason for this discrepancy is not known.
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My results are not in contrast with the observation that inactivation of pRB 
can result in increased levels o f p21 independently of p53, as has been 
described in the peripheral nervous system in R b l- / -  embryos (Macleod et ah, 
1996). Rather, I show that the presence of wildtype pRB is required for 
maintaining the G l arrest imposed in response to unprogrammed E2F1 
induction. This result appears mechanistically similar to previous work 
showing that the DNA damage induced G 1-checkpoint, which is dependent on 
functional p53 and p21, is in part mediated by pRB (Brugaloras et al., 1999; 
Harrington et al., 1998). However, my findings are significantly different, as 
they suggest that pRB regulates normal cell proliferation by two independent 
mechanisms: one that actively represses E2F-dependent promoters, and 
another one that ensures cells arrest if  E2F activity should increase as a result 
o f genetic alterations. Indeed, E2F1 overexpression is not sufficient to 
overcome the pRB-dependent G l checkpoint in non-transformed cells, 
suggesting that pRB may regulate the activity of proteins in addition to E2F 
that regulate the G l-S transition. Like wildtype E2F1, a pRB-binding deficient 
but transactivation-competent mutant o f E2F1 (E2F1-VP16) is unable to 
stimulate S phase in diploid fibroblasts (Fig. 9), again suggesting that pRB 
regulates S phase entry through proteins in addition to E2F. In agreement with 
previously published data obtained in immortalized fibroblasts (Johnson et al., 
1993; Qin et al., 1994; Shan and Lee, 1994), E2F1 induction of S phase in 
cells deficient in the G 1-checkpoint requires both the transactivation and DNA 
binding function of E2F1, suggesting that entry into S phase is not caused by
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sequestration of pRB, but rather is caused by transactivation of E2F-dependent 
promoters. Since E2F1 can induce S phase in C dkn la -/-  PMEFs, it is likely 
that the G l checkpoint function of pRB is regulated by a CDK-dependent 
phosphorylation mechanism and may involve direct binding of pRB to other 
potential pRB targets such as ID2, HBPl, C/EBPa, and MyoD (Lasorella et 
al., 2000; Lipinski and Jacks, 1999). O f these proteins, only ID2 has been 
connected to the induction of S phase. However, my results show that 
coexpression of ID2 and E2F1 is not sufficient to induce S phase in serum 
starved PMEFs (Fig. 10), suggesting that other as yet unidentified pRB- 
regulated proteins are involved in regulating the G 1/S transition.
E2F2 and E2F3, like E2F1, cannot induce S phase in normal diploid 
fibroblasts. I found that they are capable o f inducing S phase in ARF- and 
p53-deficient fibroblasts to the same extent o f E2F1 (Fig. 13a). Consistent 
with this, I have observed that activation of these three E2Fs directly induces 
expression (Fig. 136).
In conclusion, I demonstrate the molecular mechanisms by which p53 and 
pRB govern E2F activity to control the G 1/S transition in mammalian cells. 
Since the deregulation o f the pRB pathway is a common event in cancer 
(Hanahan and Weinberg, 2000), my results are important for understanding 
the etiology of uncontrolled cell division in this disease.
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RESULTS -  PART2
A IM
“E2F” is a composite activity that is generated by a large number of 
interrelated complexes. In mammals, six E2Fs (E2F1-6) contain two highly 
conserved domains that are involved in sequence specific DNA binding and 
dimérisation with DP proteins. Association of these E2Fs with one of the two 
known DP proteins is required for high affinity, sequence specific DNA 
binding, and, in the case of E2F1-5, association with members of the pRB 
family (Trimarchi and Lees, 2002). The recently identified E2F7 do not bind 
to the DP transcription factors, and it interacts efficiently with the E2F DNA 
consensus site without DP. This binding requires both of the two DNA 
binding domains of E2F7. It lacks also a transcriptional activation and a 
retinoblastoma-binding domain. E2F7 is able to repress transcription of E2F 
promoters in vitro and it binds to E2F regulated promoters in vivo (de Bruin et 
al., 2003a; Di Stefano et al., 2003).
DPI is a phosphoprotein ubiquitously expressed at high levels in tissues and
cell lines (Girling et al., 1993; Wu et al., 1995), structurally related to E2F, yet
devoid of an E2F-like pRB-binding domain (Girling et al., 1993; Helin et al.,
1993b). By contrast, DP2 is expressed at low levels with alternative splicing in
a restricted set of tissues and cell lines (Rogers et al., 1996; Wu et al., 1995;
Zhang and Chellappan, 1995). Despite their distinct pattern of expression,
77
DPI and DP2 function indistinguishably in in vitro assays, such as those for 
heterodimerisation, DNA binding and transactivation, when overexpressed 
with various E2F patterns and pRB family members.
Many evidences indicate that E2F activity is not required for cell proliferation. 
First, promoters mapping and in vivo footprinting studies detected E2F/pRB 
repressor complexes on promoters at GO/Gl while the promoters were not 
occupied in S phase. This would suggest that the E2F in complex with pocket 
proteins represses target genes and keeps cells in G l. Disruption of E2F- 
mediated transcriptional repression by an E2F-DNA-binding deficient mutant 
(Rowland et al., 2002; Zhang et al., 1999) has been reported to lead to 
immortalization of primary MEFs, while control-infected MEFs loose their 
replicative potential. Derepression of E2F target genes was observed, whose 
downregulation was critical for the establishment of Gl arrest by either p i6 or 
TGF|3. Importantly, the authors of the paper claim they have knocked out all 
E2F DNA binding activity, which they show by band shift. It is also not clear 
whether immortalized clones are rare. In contrast to the milder phenotypes 
resulting from inactivation of E2fs, loss o i D p i  in mice leads to early 
embryonic lethality owing to a failure of extra-embryonic tissues development 
(Kohn et al., 2003). Surprisingly, no differences in DNA synthesis can be seen 
in the embryonic compartment, suggesting that many cells cycles and DNA 
replications can occur without DPI. However, the biochemical effect of the 
absence of DP was not analysed with respect to E2F transactivation. In
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Drosophila, where only two d e lf  and one dDP exist, the loss of d e lfl  function 
compromises cell proliferation (Frolov et al., 2001). The defects are due to the 
unchecked activity of de2f2, since they can be suppressed by mutation of 
de2f2. Examination of eye discs from de2fl ;de2j2 double mutant animals 
reveals that relatively normal patterns of DNA synthesis can occur in the 
absence of both E2F proteins. Thus, the net effect of E2F on cell proliferation 
is null. Similarly, the pattern of DNA synthesis and cell proliferation are not 
severely affected in dDP mutant embryos or dDP mutant larvae, but they do 
not survive (Duronio et al., 1998; Royzman et al., 1997).
Other studies suggests that E2F activity is required for cell proliferation. 
Overexpression of E2F1-2-3 strongly correlates with its ability to drive the 
cells into S phase (Johnson et al., 1993; Lukas et al., 1996; Qin et al., 1994). 
TKO cells for E 2fl, E2f2, E2f3 (derived from a conditional triple knockout 
mouse) are defective for S-phase entry and progression through the cell cycle 
and show a dramatic decrease in the expression of many E2f-regulated genes 
(Wu et al., 2001). This supports the belief that E2F transactivation activity is 
required for cell proliferation. However, there is the possibility that the defects 
observed when E2fl, E2f2, E2f3 are missing are due to a gain in activity of 
the remaining E2f complexes which are believed to repress transcription and 
whose inactivation could suppress the proliferation defects. A dominant- 
negative mutant of DPI has been reported to inhibit the progression of 
SA0S2, C33A and U20S cells into S phase (Wu et al., 1996), supporting the
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idea that interaction of E2F/DP with promoters is important for cell cycle 
progression.
To understand whether E2F transactivating activity is required for cell 
proliferation and to examine the changes in gene expression that occur when 
E2F-DNA binding activity is lost, I decided to knock out endogenous DP in 
normal and tumour cells by RNA interference. To inactivate all E2F 
complexes I depleted DP, the common heterodimeric partner for E2Fs, 
required for high affinity DNA binding and functional E2F activity. In 
addition, DP depletion was more efficient than the co-depletion of the 
individual E2Fs.
RESULTS
siRNAforDP as a tool to study E2F-DNA binding activity 
I designed siRNA oligonucleolides specific for the human sequence of DPI or 
DP2 according to Elbashir et al. (see Material and Methods). I transfected the 
two siRNAs alone or in combination in HeLa cells. A non-specific siRNA 
targeting the firefly luciferase gene (GL2 siRNA) was used as control. At the 
mRNA level, DPI siRNA efficiently inhibited DPI expression (Fig. 15a). 
Similarly DP2 siRNA interfered with the abundance of DP2 mRNA (Fig. 
156).
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F igure 15 DP siRNA abolishes DP mRNA and protein expression, 
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The efficiency of depletion at protein level was assessed by Western blotting. 
Fig. 15c shows that DPI is a stable protein. Upon cycloheximide (CHX) 
treatment (which inhibits proteins synthesis) DPI half-life is around 10 hours 
in HeLa cells and 13 hours in IMR90. Geminin, an unrelated protein, was 
degraded faster (5 hours half-life). The level of DPI was greatly reduced upon 
DPI siRNA treatment compared to cells treated with a non-specific control 
(luciferase) (Fig. \5d, e). I was not able to detect endogenous DP2 in Western 
blot using different commercial antibodies. However, transfection of DP2 
siRNA caused a slight increase in DPI protein level and taken together with 
the observation that DP2siRNA reduced the mRNA level o f DP2, it could 
suggest that the DP2 siRNA oligo was functional and that loss of DP2 was 
compensated by DPI (Fig. 15/and Fig. 20a).
To investigate whether lack of DP could abrogate E2F DNA binding activity, I 
performed a gel retardation assay (EMSA) with HeLa cells extracts. HeLa 
cells express the oncoprotein E7 and thus almost all o f E2F is in the free, 
transactivating form. HeLa cells were transfected with DPI siRNA and DP2 
siRNA either alone or in combination. As negative control the reaction was 
performed in the absence of lysate (no lysate) or with not transfected cells 
(mock). As positive control cells were transfected with E2F1 and DPI. An 
excess of cold probe was added to compete for the hot probe (competitor) 
(Fig. 16a). Little or no DNA-binding activity was generated following 
transfection with DPI siRNA either alone or in combination with DP2 siRNA,
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F igure 16 Loss o f  D P I abrogates E2F DNA binding activity, 
a, Gel retardation assay using whole extract from  HeLa cells transfected 
with D PI siRNA and DP2 siRNA either alone or in com bination. As 
negative control the reaction was perform ed in the absence o f lysate (no 
lysate) or with not transfected cells (mock). As positive control cells 
were transfected with E2F1 and D P I. An excess o f cold probe was 
added to com pete for the hot probe (com petitor), b, c D P I oligo was 
transfected in asynchronous U 20S  ER-E2F1 cells for 48 h. GL2 siRNA 
was negative control (m ock). qPCR was perform ed using specific 
primers for D P I, C C N E l and GADP to normalize. Cells were incubated 
with/without OHT for 24 h. d, e As in (6, c) except that W I38 ER-E2F1 
cells were employed.
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while upon DP2 siRNA transfection most of E2F DNA binding activity was 
retained. These results show that loss of DPI, but not o f DP2, abolishes E2F 
DNA binding activity and are in agreement with the fact that DPI is 
ubiquitous and is the major protein family expressed.
Recently, our laboratory has generated an efficient system by which E2Fl(-2- 
3) activity can be manipulated. In this systhem E2Fl(-2-3) is fused to the 
estrogen receptor ligand-binding domain (Moroni et al., 2001; Millier et al., 
2001; Vigo et al., 1999). To test in vivo the ability of DPI siRNA to abrogate 
E2F activity in tumour and normal cells, I transfected U20SER-E2F1 (Fig. 
166, c) and WI38ER-E2F1 (Fig. 16J, e) with DPI siRNA and, after 48 h, I 
treated them for a period of 24 h with OHT to activate E2F1. In accordance 
with the result obtained by EMSA, ER-E2F1 activation induced C C N E l 
expression in mock-transfected cells. This activity was significantly reduced 
in DPI siRNA interfered cells.
DP is required for tumour cell proliferation
I was interested in studying whether DP had a role in cell proliferation. So, I 
transfected HeLa cells with DPI siRNA and DP2 siRNA alone or in 
combination: cells interfered for DPI, but not for DP2 did not grow compared 
to mock transfected cells ( Fig. 17a). The intensity of BrdU signal was
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Figure 17 DPI is required fo r  HeLa cell proliferation.
DPI or DP2 siRNA oligos were transfected in asynchronous HeLa cells alone 
or in combination. GL2 siRNA was negative control, a , The number of cells 
was assessed at the indicated time points by Trypan blue exclusion, by DNA 
synthesis was assessed by BrdU incorporation (1 h pulse) after 24 h / 48 h of 
siRNA transfection, c, BrdU FACS analysis at 48 h. The 72 h timepoint has 
the same profile.
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measured in situ and by FACS analysis (Fig. llb ,c), suggesting that cells 
lacking DPI accumulated in G l at 48 h and 72 h.
To control the specificity of the siRNA oligo for DPI, I designed another DPI 
siRNA oligo and I compared the phenotypes generated by the two oligos in 
HeLa cells. Both of them downregulated DPI protein level at 48 h (Fig. 18a) 
led to growth inhibition (Fig. 18c) and reduced the rate of BrdU incorporation 
(Fig. ISb). These results show that loss of DPI impairs cell proliferation due 
to a defect in cell cycle progression.
It has been reported (Elbashir et al., 2001) that even a single mismatch 
between a siRNA and the target mRNA sequence abrogates silencing. Thus, I 
mutagenized DPI in the target sequence of the siRNA oligo (oligo 1), 
introducing a silent point mutation (see Material and Methods). I transfected 
HeLa cells with expression vectors containing mutant DPI or Wt DPI cDNAs 
driven from the strong cytomegalovirus promoter and then I interfered the 
cells with DPI siRNA. In transient transfection, DPI siRNA decreased the 
level of DPI in cells transfected with Wt D PI, but not with DPI mutant 
protein (Fig. 19a). By G418 selection, I established stable pools expressing 
mutant DPI and then I transfected the cells with DPI siRNA or with a control 
oligo. DPI mutant expression did not vary (Fig. 19b), the number of viable
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F igure 18 Different D P I siRNA show the same phenotype.
Two D PI siRNA were transfected in asynchronous HeLa cells for the 
indicated tim e points. GL2 siRNA was negative control (m ock), a. 
W estern b lot on total proteins. The b lo t was probed for D P I and 
vinculin. b, DNA synthesis was assessed by BrdU incorporation (1 h 
pulse) after 24 h / 48 h o f siRNA transfection, c. Cellular phenotype 
observed at 48 h.
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Figure 19 A DPI silent mutant rescues the proliferation defect induced by 
DPI siRNA.
a, HeLa cells were transfected with Wt DPI or with a silent mutant of DPI 
and after 24 hours they were interfered with DPI siRNA (+) or GL2 siRNA (- 
). Western blot was performed on total proteins, by As in (a), except that the 
cells were selected with 750 p,g/ml of G418 to obtain a stable pool of cells 
expressing the DPI mutant, c, The number of cells was assessed by Trypan 
blue exclusion on the pool after transfection with DPI siRNA or GL2 siRNA 
(mock), dy BrdU incorporation (1 h pulse) after transfection with DPI siRNA 
or GL2 siRNA.
cells did not vary significantly (Fig. 19c), and BrdU incorporation did neither 
(Fig. 19d). This result confirms that the growth arrest observed upon DPI 
siRNA transfection is a specific response.
Then, I asked whether the growth arrest due to loss of DP expression was 
specific to HeLa cells or was a common response in tumour cell lines. SAOS2 
cells are transformed cells that express neither pRB nor p53. Loss of pRB 
increases the level of E2F activity. I transfected SA0S2 cells with DPI siRNA 
and DP2 siRNA, either alone or in combination. The protein level of DPI was 
strongly reduced at 48 h (Fig. 20a). Transfection of DP2 siRNA caused an 
increase in DPI protein level: the compensation effect suggests that DP2 
siRNA oligo is functional. The number of BrdU positive cells was 
significantly reduced after DPI siRNA transfection (48 h and 72 h), alone or 
in combination with DP2 (Fig. 20Z?), in accordance with the phenotype 
observed in HeLa cells.
DP is required fo r  normal cell proliferation
I was also interested in studying whether depletion of DP had an effect on 
normal cell proliferation. I did not succeeded in transfecting human diploid 
fibroblasts with high efficiency by oligofectamine reagent (Invitrogen). This 
did not allow me to collect clear evidences that DP was required for cell 
proliferation in normal cells.
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F igure 20 D P I is required fo r  cell proliferation in SA 0S2  cells. 
Asynchronous S A 0S 2  cells were transfected with D PI or DP2 siRNA 
oligos either alone or in combination. GL2 siRNA was negative control 
(mock), a, D PI and vinculin protein levels were assessed by W estern 
blotting, by DNA synthesis was assessed by BrdU incorporation (1 h 
pulse) after 24 h, 48 h, and 72 h of siRNA transfection.
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A system for stable expression of short interfering RNAs in mammalian cells 
has been reported (Brummelkamp et al., 2002a; Brummelkamp et al., 2002b). 
I infected WI38 and U20S cells with pRetroSuper DPI or empty vector but I 
could not see any variation in DP protein level (Fig. 21a). U 20S cells 
expressing the murine ecotropic receptor were generated (Brummelkamp et 
al., 2002a) to allow infection by ecotropic virus. This resulted in a 50% 
reduction of DPI protein level (Fig. 2lb), but it was not enough to observe a 
significant growth arrest (Fig. 21c). In my hands stable expression of short 
interfering RNAs was no as efficient as transient transfection that completely 
downregulated protein level (Fig. 21d) and led to growth arrest (Fig. 21c/). A 
possible reason for this discrepancy is that during infection there is a selection 
against the cells that express low level of DPI, since they do not grow.
Transient transfection with lipofectamine 2000 (see Material and Methods) 
allowed me to achieve a 70% of transfection efficiency in diploid fibroblasts. 
Recent papers suggest that the specificity of siRNA is concentration 
dependent (Chi et al., 2003; Semizarov et al., 2003) and a concentration of 100 
nM siRNA non specifically induces a significant number of genes, many of 
which are involved in apoptosis and stress response. I did titration experiments 
(with 100 nM siRNA, 50 nM and 20 nM) to optimize transfection in TIG3 
cells. A concentration of 20 nM siRNA was inefficient in inhibiting protein 
expression. Using a concentration of 50 nM siRNA allowed me to abolish 
DPI protein expression to the same extent of 100 nM (Fig. 22a) and to
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Figure 21 Expression o f pRetroSuper DPI.
a, WI38 and U20S cells were infected with pRetroSuper vector expressing 
DPI siRNA (two independent clones: c ll and cl2) or with empty vector 
(empty) and selected with 1 pg/ml of puromycine for 4 days. DPI and 
vinculin protein levels were assessed by Western blotting, U 20S cells 
expressing ecotropic receptor were infected as in (a), c, BrdU FACS (20 min 
pulse) in U20S cells expressing ecotropic receptor infected with two clones of 
pRetroSuper DPI (cl.l and cl.2) or with empty vector, d, Asynchronous 
U20S cells were transfected with DPI siRNA or GL2 siRNA (mock). DPI 
and vinculin protein levels were assessed by Western blotting, Cellular 
phenotype observed at 72 h and relative number of cells (/).
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Figure 22 Transfection o f DPI siRNA in TIG3 cells.
a, TIG3 cells were transfected by lipofectamine 2000 (Invitrogen) with the 
indicated amount of DPI siRNA (+) or GL2 siRNA (-) as control for 48 h. 
DPI and vinculin protein levels were detected by Western blotting on total 
protein extracts, b, The number of cells was assessed by Tripan blue 
exclusion.
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appreciate differences in cell viability between mock and DPI siRNA 
interfered cells (Fig. 22b).
IMR90 cells transfected with 50 nM DPIsiRNA did not grow compared to 
control cells (Fig. 23a). Loss of DPI in WI38 (Fig. 23d) or TIG3 (Fig. 23e) 
reduced BrdU incorporation (Fig. 23b,c,f) and the number of cells (Fig. 23g).
As additional control, I compared the effect of suppression of DPI between 
WI38 fibroblasts and VA 13 cells (which are derived from WI38 after SV40 
transformation and thus do not express p53 and pRB) (Fig. 24a). In both cases 
the growth rate of cells lacking DP expression was around 50% compared to 
control cells (Fig. 24b,c).
Loss o f  DP results in targets repression
Since loss of DPI compromises E2F-DNA binding activity (Fig. I6a), I 
wished to determine whether it altered the expression of E2F responsive 
genes. These changes in gene expression identify transcriptional events that 
depend on the endogenous DP protein. I used parallel cell extracts where I 
measured BrdU incorporation or cell viability (above experiments). RNA was 
isolated from depleted and control cells, and changes in gene expression of 
known E2F target genes were monitored by qPCR analysis. Gene expression 
was normalized according to the level of GAD P. I verified that DPI mRNA 
was decreased upon DPI siRNA transfection. Known E2F responsive gene
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Figure 23 DPI is required for cell proliferation in diploid fibroblasts, 
a, IMR90 fibroblasts were transfected with 50 nM of DPI siRNA or GL2 
siRNA (mock) and the number of cells was assessed by Trypan blue 
exclusion, by c, d  WI38 fibroblasts were transfected as in (a), BrdU 
incorporation (1 h pulse) was assessed in situ (b) and by BrdU FACS (c). DPI 
and vinculin protein levels were detected (d). The results are representative of 
three independent experiments. e ,f ,  g  TIG3 cells were transfected as in (a). 
DPI protein level, BrdU incorporation and the number of cells were assessed. 
The results are representative of two independent experiments.
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Figure 24 Lack o f p53 and pRB does not rescue the proliferation defect in 
diploid fibroblasts.
a, WI38 fibroblasts and the paired cell line VA 13 were transfected with DPI 
siRNA or GL2 siRNA (mock) for 48 h and DPI protein level was detected; 
the number of cells was measured in WI38 {b) and in VA 13 (c) by Trypan 
blue exclusion.
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transcripts were tested, such as CCNEl, CDCISA, CDC6, RRM2, TK, DHFR, 
and E2F1. Loss of DPI produced a significant reduction in all transcripts 
compared to control in HeLa cells (Fig. 25a), in WI38 (Fig. 256) and TIG3 
fibroblasts (Fig. 25c). These data indicate that loss of DPI significantly 
impairs the expression of most E2F responsive genes both in tumour and in 
normal cells.
DISCUSSION
I present evidence that loss of DPI compromises E2F DNA binding activity, 
impairs the rate of cell proliferation of both primary and transformed cell lines 
and represses the expression of E2F responsive genes. In stark contrast to the 
milder phenotypes that result from inactivation of the E2Fs, loss of D PI in 
mice leads to death in utero because of dramatic DNA replication defects in 
extra embryonic tissues (Kohn et al., 2003). Unlike extra-embryonic tissues, 
no proliferation defects are observed in the DPI deficient embryos prior to 
lethality suggesting that many cell cycles and DNA replication can occur 
without DPI. However, the biochemical effect of DP depletion was not 
analyzed with respect to E2F transactivating activity, so we do not know the 
amount of E2F left. In addition, we cannot exclude that DP1/DP2 levels in the 
embryo can be influenced through a maternal effect. To study the requirement 
of DPI in embryonic development it would be useful to get DPI floxed mice.
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Figure 25 Loss o f DPI results in E2F targets repression, 
a, DPI siRNA or GL2 siRNA (mock) were transfected in asynchronous HeLa 
cells for 48 h. qPCR was performed using specific primers for D P I, DP2 
CCNEl, MCM3 and RRM2. GADP levels were used for normalization, b, 
WI38 fibroblasts were transfected as in {a) and qPCR was performed with 
specific primers for D PI, DP2, CCNEl, CDC25A, CDC6, RRM2, DHFR, TK 
and E2F1. c, TIG3 cells were transfected and processed as in (6). The results 
are representative of at least two independent experiments.
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In the literature several evidences arise stressing that E2F mainly functions as 
a repressor. Classic promoter mapping and in vivo footprinting studies 
concluded that repressive E2F complexes regulate many E2F-responsive 
genes during GO/Gl and that the promoters are unoccupied during G l/S  
transition when the genes are actively transcribed (Dalton, 1992; Huet et al., 
1996; Le Cam et al., 1999; Neuman et al., 1994; Tommasi and Pfeifer, 1995; 
Zwicker et al., 1996) (Fig 26a). Plasmids containing multiple E2F-binding 
sites were used to titrate RB-E2F repressor complexes (He et al., 2000) and 
the cells failed to arrest in G1 following accumulation of endogenous 
hypophosphorylated RB. A dominant-negative mutant of E2F1, which 
contains the DNA-binding domain but lacks the RB-binding site and 
transactivation domain, was used to displace RB-E2F complexes from E2F- 
responsive genes. The expression of this mutant prevented RB-dependent 
arrest in G 1 by either p i 6 or TGF-P (Zhang et al., 1999). This has been 
interpreted as a result of transcriptional derepression of E2F target genes, 
whose downregulation is critical for the establishment of G1 arrest. These 
studies, however, do not show that E2F does not have a role in transcriptional 
activation in the cell cycle and it is unclear whether or not the binding of free 
E2F to endogenous promoters was completely eliminated.
My results agree with previous findings showing, through overexpression 
systems, that transcriptional activation by E2F is important for the progression 
of cells through the cell cycle (Johnson et al., 1993; Qin et al., 1995). In these
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Figure 26 Models for the regulation o f transcription by the E2Fs. 
a, Displacement of repressive pRB-E2F complexes at G l/S transition results 
in targets derepression, b, E2F allows a burst of gene expression as cells enter 
S phase, c, In E2F1-2-3 TKO MEFs there is no S phase and gene expression is 
decreased. However, E2F4-5-6 could replace the missing E2Fs on promoters 
and repress transcription, d, DPIsiRNA knocks down all E2F activity 
mediated by DPI, arrests the cells and decreases gene expression, e, E2F7 
binds DNA in a DP independent manner, may replace the missing E2Fs on 
promoters and repress transcription.
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studies expression of Wt E2F1 induced S phase (Fig. 266). This induction was 
dependent on the ability of E2F1 to bind DNA and to transactivate E2F 
dependent promoters, since the DNA binding deficient mutant (E2F1 E l32) 
and the transactivating deficient mutant (E2F1 1-374) did not induce S phase. 
However, the system leads to loss of target specificity resulting from 
secondary changes in gene expression due to progression through the cell 
cycle. My experiments performed in HeLa and in VA13 cells suggest that the 
transactivation by free E2F is required for proliferation (Fig. 266). Indeed, 
HeLa cells express the oncoprotein E7, while VA13 are SV40-transformed, 
thus in both cases almost all of E2F is in the free transactivating form.
Studies in which E 2 f  genes have been deleted in mice have failed to 
demonstrate that transactivation is the primary function of E 2 f  in cell cycle 
regulation, because of redundancy and functional compensation among the 
£"2/family members. An evidence that E 2fl, E2f2, and E2f3 are required to 
induce S-phase and activate E2F target gene expression has been provided 
recently by the generation of a conditional E 2fl, E2f2, E2f3 triple knockout 
(TKO) mouse (Wu et al., 2001). TKO cells are defective for S-phase entry and 
progression through the cell cycle and show a dramatic decrease in the 
expression of many E2f-regulated genes. However, the phenotypes seen when 
E 2fl, E2f2, E2f3 are removed could be viewed as a gain in activity of the 
repressor E2f complexes (Fig. 26c). By DPI siRNA I knocked-out all E2F 
DNA binding activity mediated by DP proteins including the ‘repressive’
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E2F4, E2F5 and E2F6 (Fig. 16a). My results are in agreement with data 
obtained by overexpression of a dominant negative form of DPI (that retained 
E2F binding, but not DNA binding), which arrested SA0S2, C33A and U20S 
cells in the G1 phase of the cell cycle (Wu et al., 1996) (Fig. 26d).
I did not observe any apoptotic effect of the DPI siRNA in the experiments 
presented here up to 72 hours of DPI siRNA expression. In tumour cell lines 
that lack p53 expression (SAOS2, VA13) and thus cannot undergo p53 
dependent apoptosis, DPI produced the same phenotype as observed in 
diploid fibroblasts (Fig. 20 and 24). These results are in agreement with the 
fact that inactivation of p53  in mice is unable to rescue the DP7-dependent 
embryonic lethality (Kohn et al., 2003). Thus, the consequence of loss of DP 
in diploid and in tumour cells is G1 arrest and not apoptosis or DNA 
replication. Moreover, intact p53 and pRB are not required to prevent the 
growth arrest upon loss of DPI and DPI is rate limiting both for the 
proliferation of tumour and normal cells. The G1 arrest induced by DPI 
siRNA is rescued by coexpression of a silent DPI mutant (Fig. 19).
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CONCLUDING REMARKS
Although mutation in genes encoding pRB or upstream regulators of pRB is 
frequently found in human tumours, intragenic mutations in the genes 
encoding the E2F and DP transcription factors have not been isolated. This 
may be due to functional compensation by related E2F / DP activity (Dyson, 
1998).
Current models o f deregulation of DNA replication in cancer cells are based 
on the observation that increased E2F activity is sufficient to induce DNA 
replication in immortalized quiescent cells in the absence of growth factors 
(Dimri et al., 1994; Johnson et al., 1993; Lukas et al., 1996; Qin et al., 1994; 
Shan and Lee, 1994). I determined the effect o f E2F activation in diploid 
fibroblasts and I found that suppression of the p53- or pRB- mediated G1 
checkpoint is required for E2F- induced S phase entry. In addition to act as an 
E2F-dependent transcriptional repressor, my data suggest that pRB is required 
to retain the G1 checkpoint in response to unprogrammed proliferative signals. 
This raises the possibility to investigate whether the mechanism involves 
direct binding of pRB to other potential pRB targets in addition to E2F, such 
as HBPl, C/EBPa or MyoD (Lipinski and Jacks, 1999).
To understand how cell proliferation is regulated, it is important to know if  the
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E2F/DP heterodim ers function either as activators or repressors of 
transcription. My studies provide a further understanding in this direction, 
defining a crucial role for DPI in cell proliferation. This is essential for a 
number o f pharmaceutical companies that are developing drugs to the E2F 
transcription factors. siRNA against DP will be a useful tool to test whether 
E2F/DP activity is required in biological responses other than proliferation, 
such as apoptosis and differentiation. We have yet to understand how E2F like 
proteins that bind DNA in a DP independent manner fits into the model. It is 
unclear whether, for instance, E2F7 can replace the missing E2F activities and 
can repress E2F target genes in the absence of DP (Fig. 26e).
The results discussed in this thesis enlight two aspects of E2F activity, first 
demonstrating the molecular mechanism by which p53 and pRB govern E2F 
activity to control the transition from G1 to S phase, second analysing how 
cell proliferation is regulated by E2F activity.
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